<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2005245323
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Avysk HCT
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VALSARTAN,HYDROCHLOROTHIAZIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        80,12.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        27.80
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Med city" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Med city
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Med City Pharma
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT</strong> film-coated tablets contain two active substances called valsartan and hydrochlorothiazide. Both of these substances help to control high blood pressure (hypertension).</p><p>&bull; Valsartan belongs to a class of medicines known as &ldquo;angiotensin II receptor antagonists&rdquo;, which help to control high blood pressure. Angiotensin II is a substance in the body that causes vessels to tighten, thus causing your blood pressure to increase. Valsartan works by blocking the effect of angiotensin II. As a result, blood vessels relax and blood pressure is lowered.</p><p>&bull; Hydrochlorothiazide belongs to a group of medicines called thiazide diuretics (also known as &ldquo;water tablets&rdquo;). Hydrochlorothiazide increases urine output, which also lowers blood pressure.</p><p><strong>Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT</strong> is used to treat high blood pressure which is not adequately controlled by a single substance alone.</p><p>High blood pressure increases the workload of the heart and arteries. If not treated, it can damage the blood vessels of the brain, heart, and kidneys, and may result in a stroke, heart failure or kidney failure. High blood pressure increases the risk of heart attacks. Lowering your blood pressure to normal reduces the risk of developing these disorders.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>If you are allergic (hypersensitive) to valsartan, hydrochlorothiazide, sulphonamide derivatives (substances chemically related to hydrochlorothiazide) or to any of the other ingredients of this medicine.</p><p>If you are more than 3 months pregnant (it is also better to avoid <strong>Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT </strong>in early pregnancy).</p><p>If you have severe liver disease, destruction of the small bile ducts within the liver (biliary cirrhosis) leading to the build-up of bile in the liver (cholestasis).</p><p>If you have severe kidney disease.</p><p>If you are unable to produce urine (anuria).</p><p>If you are treated with an artificial kidney.</p><p>If the level of potassium or sodium in your blood is lower than normal, or if the level of calcium in your blood is higher than normal despite treatment.</p><p>If you have gout.</p><p>If you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.</p><p>If any of the above apply to you, tell your doctor and do not take <strong>Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT</strong>.</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor:</p><p>If you are taking potassium-sparing medicines, potassium supplements, salt substitutes containing potassium or other medicines that increase the amount of potassium in your blood such as heparin. Your doctor may need to check the amount of potassium in your blood regularly.</p><p>If you have low levels of potassium in your blood.</p><p>If you have diarrhea or severe vomiting.</p><p>If you are taking high doses of water tablets (diuretics).</p><p>If you have severe heart disease.</p><p>If you are suffering from heart failure or have experienced a heart attack. Follow your doctor&rsquo;s instruction for the starting dose carefully. Your doctor may also check your kidney function.</p><p>If you suffer from a narrowing of the kidney artery.</p><p>If you have recently received a new kidney.</p><p>If you suffer from hyperaldosteronism. This is a disease in which your adrenal glands make too much of the hormone aldosterone. If this applies to you, the use of <strong>Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT<sup> </sup></strong>is not recommended.</p><p>If you have liver or kidney disease.</p><p>If you have ever experienced swelling of the tongue and face caused by an allergic reaction called angioedema when taking another drug (including ACE inhibitors), tell your doctor. If these symptoms occur when you are taking <strong>Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT</strong>, stop taking <strong>Avysk</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>HCT<sup> </sup></strong>immediately and never take it again.</p><p>If you have fever, rash and joint pain, which may be signs of systemic lupus erythematosus (SLE, a so-called autoimmune disease).</p><p>If you have diabetes, gout, high levels of cholesterol or triglycerides in your blood.</p><p>If you have had allergic reactions with the use of other blood pressure-lowering agents of this class (angiotensin II receptor antagonists) or if you have allergy or asthma.</p><p>If you experience a decrease in vision or eye pain. These could be symptoms of fluid accumulation in the vascular layer of the eye (choroidal effusion) or an increase of pressure in your eye and can happen within hours to weeks of taking <strong>Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT</strong>. This can lead to permanent vision loss, if not treated. If you earlier have had a penicillin or sulphonamide allergy you can be at higher risk of developing this.&nbsp;</p><p>If you are taking any of the following medicines used to treat high blood pressure:</p><p>An ACE inhibitors (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems.</p><p>Aliskiren.</p><p>If you have had skin cancer or if you develop an unexpected skin lesion during the treatment. Treatment with hydrochlorothiazide, particularly long term use with high doses, may increase the risk of some types of skin and lip cancer (non-melanoma skin cancer). Protect your skin from sun exposure and UV rays while taking <strong>Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT</strong>.</p><p>If you experienced breathing or lung problems (including inflammation or fluid in the lungs) following hydrochlorothiazide intake in the past.</p><p>If you develop any severe shortness of breath or difficulty breathing after taking <strong>Avysk </strong><strong><sup>&reg;</sup></strong>, seek medical attention immediately.</p><p>Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.</p><p><strong>Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT</strong> may cause increased sensitivity of the skin to sun.</p><p>The use of <strong>Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT</strong> in children and adolescents (below the age of 18 years) is not recommended.</p><p>You must tell your doctor if you think you are (or might become) pregnant. <strong>Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT</strong> is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage.</p><p><strong>Other medicines and Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken any other medicines, or might take any other medicines.</p><p>The effect of the treatment can be influenced if <strong>Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT<sup> </sup></strong>is taken together with certain other medicines. It may be necessary to change the dose, to take other precautions, or in some cases to stop taking one of the medicines. This especially applies to the following medicines:</p><p>Lithium, a medicine used to treat some types of psychiatric diseases.</p><p>Medicines or substances that may increase the amount of potassium in your blood. These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines and heparin.</p><p>Medicines that may reduce the amount of potassium in your blood, such as diuretics (water tablets), corticosteroids, laxatives, carbenoxolone, amphotericin or penicillin G.</p><p>Some antibiotics (rifamycin group), a drug used to protect against transplant rejection (ciclosporin) or an antiretroviral drug used to treat HIV/AIDS infection (ritonavir). These drugs may increase the effect of <strong>Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT</strong>.</p><p>Medicines that may induce &ldquo;torsades de pointes&rdquo; (irregular heart beat), such as antiarrhythmics (medicines used to treat heart problems) and some antipsychotics.</p><p>Medicines that may reduce the amount of sodium in your blood, such as antidepressants, antipsychotics, antiepileptics.</p><p>Medicines for the treatment of gout, such as allopurinol, probenecid, sulfinpyrazone.</p><p>Therapeutic vitamin D and calcium supplements.</p><p>Medicines for the treatment of diabetes (oral agents such as metformin or insulins).</p><p>Other medicines to lower your blood pressure including methyldopa, ACE inhibitors (such as enalapril, lisinopril, etc.) or aliskiren.</p><p>Medicines to increase blood pressure, such as noradrenaline or adrenaline.</p><p>Digoxin or other digitalis glycosides (medicines used to treat heart problems).</p><p>Medicines that may increase blood sugar levels, such as diazoxide or beta blockers.</p><p>Cytotoxic medicines (used to treat cancer), such as methotrexate or cyclophosphamide.</p><p>Pain killers such as non-steroidal anti-inflammatory agents (NSAIDs), including selective cyclooxygenase-2 inhibitors (Cox-2 inhibitors) and acetylsalicylic acid &gt; 3 g.</p><p>Muscle relaxing medicines, such as tubocurarine.</p><p>Anti-cholinergic medicines (medicines used to treat a variety of disorders such as gastrointestinal cramps, urinary bladder spasm, asthma, motion sickness, muscular spasms, Parkinson&rsquo;s disease and as an aid to anaesthesia).</p><p>Amantadine (medicine used to treat Parkinson&rsquo;s disease and also used to treat or prevent certain illnesses caused by viruses).</p><p>Cholestyramine and colestipol (medicines used mainly to treat high levels of lipids in the blood).</p><p>Ciclosporin, a medicine used for organ transplant to avoid organ rejection.</p><p>Alcohol, sleeping pills and anaesthetics (medicines with sleeping or painkilling effect used for example during surgery).</p><p>Iodine contrast media (agents used for imaging examinations).</p><p><strong>Taking Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT<sup> </sup>with food, drink and alcohol</strong></p><p>Avoid taking alcohol until you have talked to your doctor. Alcohol may make your blood pressure fall more and/or increase the risk of you becoming dizzy or feeling faint.</p><p><strong>Pregnancy and breast-feeding</strong></p><p><strong>You must tell your doctor if you think that you are (or might become) pregnant.</strong></p><p>Your doctor will normally advise you to stop taking <strong>Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT<sup> </sup></strong>before you become pregnant or as soon as you know you are pregnant, and will advise you to take another medicine instead of <strong>Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT</strong>. <strong>Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT<sup> </sup></strong>is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if it is used after the third month of pregnancy.</p><p><strong>Tell your doctor if you are breast-feeding or about to start breast-feeding.</strong></p><p><strong>Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT </strong>is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.</p><p><strong>Driving and using machines</strong></p><p>Before you drive a vehicle, use tools or operate machines or carry out other activities that require concentration, make sure you know how <strong>Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT<sup> </sup></strong>affects you. Like many other medicines used to treat high blood pressure, <strong>Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT<sup> </sup></strong>may occasionally cause dizziness and affect the ability to concentrate.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. This will help you to get the best results and lower the risk of side effects. Check with your doctor or pharmacist if you are not sure.</p><p>People with high blood pressure often do not notice any signs of this problem. Many may feel quite normal. This makes it all the more important for you to keep your appointments with your doctor even if you are feeling well.</p><p>Your doctor will tell you exactly how many tablets of <strong>Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT </strong>to take. Depending on how you respond to the treatment, your doctor may suggest a higher or lower dose.</p><p>The recommended dose of <strong>Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT<sup> </sup></strong>is one tablet per day.</p><p>Do not change the dose or stop taking the tablets without consulting your doctor.</p><p>The medicine should be taken at the same time each day, usually in the morning.</p><p>You can take <strong>Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT<sup> </sup></strong>with or without food.</p><p>Swallow the tablet with a glass of water.</p><p><strong>If you take more Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT<sup> </sup>than you should</strong></p><p>If you experience severe dizziness and/or fainting, lie down and contact your doctor immediately. If you have accidentally taken too many tablets, contact your doctor, pharmacist or hospital.</p><p><strong>If you forget to take Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT</strong></p><p>If you forget to take a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the dose you missed. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT</strong></p><p>Stopping your treatment with <strong>Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT</strong> may cause your high blood pressure to get worse. Do not stop taking your medicine unless your doctor tells you to.</p><p><strong>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Some side effects can be serious and need immediate medical attention:</strong></p><p>You should see your doctor immediately if you experience symptoms of angioedema, such as:</p><p>Swollen face, tongue or pharynx.</p><p>Difficulty in swallowing.</p><p>Hives and difficulties in breathing.</p><p>Severe skin disease that causes rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever (toxic epidermal necrolysis).</p><p>Decrease in vision or pain in your eyes due to high pressure (possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle closure glaucoma).</p><p>Fever, sore throat, more frequent infections (agranulocytosis).</p><p>Severe shortness of breath, fever, weakness, and confusion (acute respiratory distress syndrome).</p><p>These side effects are very rare or of frequency not known.</p><p><strong>If you get any of these symptoms, stop taking Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT</strong> <strong>and contact your doctor straight away.</strong></p><p><strong>Side effects include:</strong></p><p><strong>Uncommon (may affect up to 1 in 100 people):</strong></p><p>Cough.</p><p>Low blood pressure.</p><p>Light-headedness.</p><p>Dehydration (with symptoms of thirst, dry mouth and tongue, infrequent urination, dark colored urine, dry skin).</p><p>Muscle pain.</p><p>Tiredness.</p><p>Tingling or numbness.</p><p>Blurred vision.</p><p>Noises (e.g. hissing, buzzing) in ears.</p><p><strong>Very rare (may affect up to 1 in 10,000 people):</strong></p><p>Dizziness.</p><p>Diarrhea.</p><p>Joint pain.</p><p><strong>Not known (frequency cannot be estimated from the available data):</strong></p><p>Breathing difficulty.</p><p>Severely decreased urine output.</p><p>Low level of sodium in the blood (which can trigger tiredness, confusion, muscle twitching and/or convulsions in severe cases).</p><p>Low level of potassium in the blood (sometimes with muscle weakness, muscle spasms, abnormal heart rhythm).</p><p>Low level of white cells in the blood (with symptoms such as fever, skin infections, sore throat or mouth ulcers due to infections, weakness).</p><p>The level of bilirubin increased in blood (which can, in severe cases, trigger yellow skin and eyes).</p><p>The level of blood urea nitrogen and creatinine increased in blood (which can indicate abnormal kidney function).</p><p>The level of uric acid in blood increased (which can, in severe cases, trigger gout).</p><p>Syncope (fainting).</p><p><strong>The following side effects have been reported with products containing valsartan or hydrochlorothiazide alone:</strong></p><p><strong><u>Valsartan</u></strong></p><p><strong>Uncommon (may affect up to 1 in 100 people):</strong></p><p>Spinning sensation.</p><p>Abdominal pain.</p><p><strong>Not known (frequency cannot be estimated from the available data):</strong></p><p>Blistering skin (sign of dermatitis bullous).</p><p>Skin rash with or without itching together with some of the following signs or symptoms: fever, joint pain, muscle pain, swollen lymph nodes and/or flu-like symptoms.</p><p>Rash, purplished-red spots, fever, itching (symptoms of inflammation of blood vessels).</p><p>Low level of blood platelets (sometimes with unusual bleeding or bruising).</p><p>High level of potassium in the blood (sometimes with muscle spasms, abnormal heart rhythm).</p><p>Allergic reactions (with symptoms such as rash, itching, hives, difficulty breathing or swallowing, dizziness).</p><p>Swelling mainly of the face and throat; rash; itching.</p><p>Elevation of liver function values.</p><p>The level of haemoglobin decreased and the percentage of red cells decreased in the blood (which both can, in severe cases, trigger an anaemia).</p><p>Kidney failure.</p><p>Low level of sodium in the blood (which can trigger tiredness, confusion, muscle twitching and/or convulsions in severe cases).</p><p><strong><u>Hydrochlorothiazide</u></strong></p><p><strong>Very common (may affect more than 1 in 10 people):</strong></p><p>Low level of potassium in the blood.</p><p>Increase of lipids in the blood.</p><p><strong>Common (may affect up to 1 in 10 people):</strong></p><p>Low level of sodium in the blood.</p><p>Low level of magnesium in the blood.</p><p>High level of uric acid in the blood.</p><p>Itchy rash and other types of rash.</p><p>Reduced appetite.</p><p>Mild nausea and vomiting.</p><p>Dizziness, fainting on standing up.</p><p>Inability to achieve or maintain erection.</p><p><strong>Rare (may affect up to 1 in 1,000 people):</strong></p><p>Swelling and blistering of the skin (due to increased sensitivity to sun).</p><p>High level of calcium in the blood.</p><p>High level of sugar in the blood.</p><p>Sugar in the urine.</p><p>Worsening of diabetic metabolic state.</p><p>Constipation, diarrhea, discomfort of the stomach or bowels, liver disorders which can occur together with yellow skin and eyes.</p><p>Irregular heart-beat.</p><p>Headache.</p><p>Sleep disturbances.</p><p>Sad mood (depression).</p><p>Low level of blood platelets (sometimes with bleeding or bruising underneath the skin).</p><p>Dizziness.</p><p>Tingling or numbness.</p><p>Vision disorder.</p><p><strong>Very rare (may affect up to 1 in 10,000 people):</strong></p><p>Inflammation of blood vessels with symptoms such as rash, purplish-red spots, fever (vasculitis).</p><p>Rash, itching, hives, difficulty breathing or swallowing, dizziness (hypersensitivity reactions).</p><p>Facial rash, joint pain, muscle disorder, fever (lupus erythematosus).</p><p>Severe upper stomach pain (pancreatitis).</p><p>Difficulty breathing with fever, coughing, wheezing, breathlessness (respiratory distress including pneumonitis and pulmonary oedema).</p><p>Pale skin, tiredness, breathlessness, dark urine (haemolytic anaemia).</p><p>Fever, sore throat or mouth ulcers due to infections (leucopenia).</p><p>Confusion, tiredness, muscle twitching and spasm, rapid breathing (hypochloraemic alkalosis).</p><p><strong>Not known (frequency cannot be estimated from the available data):</strong></p><p>Weakness, bruising and frequent infections (aplastic anemia).</p><p>Severely decreased urine output (possible signs of renal disorder or renal failure).</p><p>Rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever (possible signs of Erythema multiforme).</p><p>Muscle spasm.</p><p>Fever (pyrexia).</p><p>Weakness (asthenia).</p><p>Skin and lip cancer (non-melanoma skin cancer).</p><p><strong>&nbsp;</strong></p><p><strong>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Do not use <strong>Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT<sup> </sup></strong>after the expiry date (EXP) which is stated on the blister and the carton.</p><p>The expiry date refers to the last day of that month.</p><p><strong>Avysk</strong><strong><sup>&reg;</sup></strong><strong> HCT<sup> </sup></strong>tablets: Store below 30&deg;C.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substances are valsartan and hydrochlorothiazide.</p><p>The other ingredients are Microcrystalline cellulose, croscarmellose sodium, Povidone K30, colloidal silicon dioxide, magnesium stearate, Opadry OY-L White, FD&amp;C red # 40, FD&amp;C blue # 1, purified water.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Avysk® HCT 80/12.5 mg: Light violet oblong normal biconvex film coated tablets, engraved with A1 on one face and plain on the other, presented in Alu/Alu blisters, intended for oral use.
Pack size: 30 Film Coated Tablets (10 tablets/blister, 3 blisters/pack). 
Avysk® HCT 160/12.5 mg: Purple oblong deep biconvex film coated tablets, engraved with H21 on one face and and plain on the other face, presented in Alu/Alu blisters, intended for oral use.
Pack size: 30 Film Coated Tablets (10 tablets/blister, 3 blisters/pack). 
Avysk® HCT 160/25 mg: Light violet oblong deep biconvex film coated tablets, engraved with H17 on one face and plain on the other face, presented in Alu/Alu blisters, intended for oral use.
Pack size: 30 Film Coated Tablets (10 tablets/blister, 3 blisters/pack). 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Med City Pharma-KSA.</strong></p><p>1st Industrial city, Phase 5, Jeddah &ndash;KSA.</p><p>Tel: 00966920003288</p><p>Mobile: 00966555786968</p><p>P.O .Box: 4072 - Jeddah 22429</p><p>E-mail: info@medcitypharma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                08/2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تحتوي أقراص<strong> </strong><strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong><strong> </strong>المغلفة على مادتين فعالتين هما ڤالسارتان وهيدروكلوروثيازيد. وكلا المادتين تساعدان في السيطرة على ارتفاع ضغط الدم.</p><p dir="RTL">ينتمي ڤالسارتان إلى مجموعة من الأدوية تعرف &ldquo;بمضادات مستقبلات أنجيوتنسين II&rdquo;، والتي تساعد في السيطرة على ارتفاع ضغط الدم. أنجيوتنسين II هي عبارة عن مادة في الجسم تسبب تضيق الأوعية الدموية، مما يؤدي إلى ارتفاع ضغط الدم. يعمل ڤالسارتان عن طريق منع تأثير أنجيوتنسين II. ونتيجة لذلك، يحدث ارتخاء في الأوعية الدموية وينخفض ضغط الدم.</p><p dir="RTL">ينتمي هيدروكلوروثيازيد إلى مجموعة من الأدوية تعرف بمدرات البول الثيازيدية (تعرف أيضا &ldquo;بأقراص الماء&rdquo;). يزيد هيدروكلوروثيازيد من إخراج البول، والذي يسبب أيضا انخفاض ضغط الدم.</p><p dir="RTL">يستعمل <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong><strong> </strong>لعلاج ارتفاع ضغط الدم الذي لا تتم السيطرة عليه بشكل كاف عن طريق مادة فعالة واحدة.</p><p dir="RTL">يزيد ارتفاع ضغط الدم من عبء العمل على القلب والشرايين. إذا لم يتم علاجه، فإنه يمكن أن يسبب تلف الأوعية الدموية في الدماغ، القلب، والكلى، ويمكن أن يؤدي إلى الإصابة بسكتة دماغية، قصور في وظيفة عضلة القلب أو قصور في وظيفة الكلى. يسبب ارتفاع ضغط الدم زيادة خطر التعرض للنوبات القلبية. إن خفض ضغط الدم إلى وضعه الطبيعي يقلل من خطر حدوث هذه الاضطرابات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إذا كنت تعاني من تحسس (فرط التحسس) لڤالسارتان، هيدروكلوروثيازيد، أو مشتقات سلفوناميد (المواد المرتبطة كيميائيا بهيدروكلوروثيازيد) أو لأي مكونات أخرى في هذا الدواء.</p><p dir="RTL">إذا كنت حامل لمدة تزيد عن 3 أشهر (يفضل أيضا تجنب تناول <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong> في المرحلة المبكرة من الحمل).</p><p dir="RTL">إذا كنت تعاني من مرض حاد في الكبد، أو تهتك في القنوات الصفراوية الصغيرة داخل الكبد (التشمع الصفراوي) مما يؤدي إلى تراكم الصفراء في الكبد (الركود الصفراوي).</p><p dir="RTL">إذا كنت تعاني من مرض حاد في الكلى.</p><p dir="RTL">إذا كنت تعاني من صعوبة في إخراج البول (انقطاع البول).</p><p dir="RTL">إذا كنت تخضع للعلاج باستعمال الكلى الاصطناعية.</p><p dir="RTL">إذا انخفض مستوى البوتاسيوم أو الصوديوم في الدم أكثر من المستوى الطبيعي، أو إذا كان مستوى الكالسيوم في الدم أعلى من المستوى الطبيعي على الرغم من الخضوع للعلاج.</p><p dir="RTL">إذا كنت تعاني من النقرس.</p><p dir="RTL">&nbsp;إذا كنت تعاني من داء السكري أو قصور في وظيفة الكلى ويتم علاجك باستعمال دواء خافض لضغط الدم يحتوي على الأليسكرين.</p><p dir="RTL">إذا كان أي مما ذكر في الأعلى ينطبق عليك، أخبر طبيبك ولا تتناول <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong>.</p><p dir="RTL"><strong>الاحتياطات</strong><strong> </strong><strong>والمحاذير</strong></p><p dir="RTL">تحدث مع طبيبك في الحالات التالية:</p><p dir="RTL">إذا كنت تتناول أدوية حافظة للبوتاسيوم، مكملات البوتاسيوم، وبدائل الملح المحتوية على البوتاسيوم أو أدوية أخرى تزيد كمية البوتاسيوم في الدم مثل الهيبارين. قد يحتاج طبيبك التأكد من كمية البوتاسيوم في الدم بشكل منتظم.</p><p dir="RTL">إذا كان تعاني من انخفاض مستوى البوتاسيوم في الدم.</p><p dir="RTL">إذا كنت تعاني من الإسهال أو القيء الحاد.</p><p dir="RTL">إذا كنت تتناول جرعات عالية من أقراص الماء (مدرات البول).</p><p dir="RTL">إذا كنت تعاني من مرض حاد في القلب.</p><p dir="RTL">إذا كنت تعاني من قصور في وظيفة عضلة القلب أو عانيت سابقا من نوبة قلبية. اتبع تعليمات طبيبك فيما يتعلق بالجرعة الابتدائية بحذر. قد يقوم طبيبك أيضا بالتأكد من سلامة وظيفة الكلى لديك.</p><p dir="RTL">إذا كنت تعاني من تضيق في الشريان الكلوي.</p><p dir="RTL">إذا خضعت مؤخرا لعملية زرع الكلى.</p><p dir="RTL">إذا كنت تعاني من فرط إفراز الألدوستيرون. في هذا المرض تفرز الغدد الكظرية كميات كبيرة جدا من هرمون الألدوستيرون. إذا كان هذا ينطبق عليك، لا يوصى باستعمال <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong>.</p><p dir="RTL">إذا كنت تعاني من مرض في الكبد أو الكلى.</p><p dir="RTL">إذا عانيت في السابق من تورم في اللسان والوجه نتيجة تفاعل تحسسي يعرف بالوذمة الوعائية عند تناول دواء آخر (بما في ذلك مثبطات الإنزيم المحول للأنجيوتنسين) أخبر طبيبك. إذا حدثت هذه الأعراض عند تناولك <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong>،<strong><sup> </sup></strong>توقف عن تناول <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong> فوراً ولا تتناوله مرة أخرى.</p><p dir="RTL">إذا كنت تعاني من الحمى، طفح جلدي وألم في المفاصل، والتي قد تكون علامات الذأب الحمامي الجهازي (وهو من أمراض المناعة الذاتية).</p><p dir="RTL">إذا كنت تعاني من داء السكري، النقرس، وارتفاع مستويات الكوليسترول أو الدهون الثلاثية في الدم.</p><p dir="RTL">إذا عانيت في السابق من تفاعلات تحسسية عند استعمال أدوية أخرى خافضة لضغط الدم تنتمي إلى هذه المجموعة الدوائية (مضادات مستقبلات أنجيوتنسين II) أو إذا كنت تعاني من تحسس أو ربو.</p><p dir="RTL">إذا عانيت من ضعف في الرؤية أو ألم في العينين. قد تكون هذه أعراض تجمع السوائل في الطبقة الوعائية للعين (الارتشاح المشيمي) أو زيادة الضغط في العين ويمكن أن يحدث خلال ساعات إلى أسابيع من تناول <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong>.<strong> </strong>قد يؤدي هذا إلى فقدان الرؤية بشكل دائم إذا لم يتم علاجه. إذا عانيت في السابق من تحسس للبنسيلين أو السلفوناميد قد تكون معرض أكثر لخطر الإصابة بذلك.</p><p dir="RTL">إذ كنت تتناول أي من الأدوية التالية التي تستعمل لعلاج ارتفاع ضغط الدم:</p><p dir="RTL">- مثبطات الإنزيم المحول للأنجيوتنسين (مثل إنالابريل، ليزينوبريل، راميبريل)، بشكل خاص إذا كنت تعاني من مشاكل في الكلى ناتجة عن داء السكري.</p><p dir="RTL">- أليسكرين.</p><p dir="RTL">إذا عانيت في السابق من سرطان في الجلد أو عانيت من ظهور آفات جلدية غير متوقعة خلال العلاج. قد يسبب العلاج باستعمال هيدروكلوروثيازيد خاصة إذا استمر لفترة طويلة بجرعات عالية، زيادة خطر الإصابة ببعض أنواع سرطانات الجلد و الشفاه (سرطان الجلد غير الميلانيني). تجنب التعرض لأشعة الشمس و الأشعة فوق البنفسجية خلال فترة تناول <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong>.</p><p dir="RTL">إذا عانيت في السابق من مشاكل في التنفس أو الرئة (بما في ذلك الالتهاب أو تجمع السوائل في الرئتين) بعد تناول هيدروكلوروثيازيد.</p><p dir="RTL">إذا عانيت من قصر حاد في النفس أو صعوبة في التنفس بعد تناول <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong>، اطلب الرعاية الطبية فورا.</p><p dir="RTL">قد يقوم الطبيب بفحص وظيفة الكلى، ضغط الدم، و كمية الكهرليات (مثل البوتاسيوم) في الدم خلال فترات منتظمة.</p><p dir="RTL">قد يسبب <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong><strong><sup> </sup></strong>زيادة تحسس الجلد لأشعة الشمس.</p><p dir="RTL">لا يوصى باستعمال <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong> للأطفال والمراهقين (الذين تقل أعمارهم عن 18 عاما).</p><p dir="RTL">يجب أن تخبري طبيبك إذا كنت تعتقدين بأنك حامل (أو قد تصبحين حامل). لا يوصى باستعمال <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong><strong><sup> </sup></strong>في المرحلة المبكرة من الحمل، ويجب عدم تناوله إذا كان عمر الحمل يزيد عن 3 أشهر، حيث قد يسبب أذى خطير للطفل إذا تم استعماله في هذه المرحلة.</p><p dir="RTL"><strong>الأدوية</strong><strong> </strong><strong>الأخرى</strong><strong> </strong><strong>و</strong><strong> </strong><strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخرا أي أدوية أخرى، أو من الممكن أن تتناول أي أدوية أخرى.</p><p dir="RTL">قد تتأثر فاعلية العلاج إذا تم تناول <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong> بشكل متزامن مع بعض الأدوية الأخرى. قد يكون من الضروري تغيير الجرعة، أو اتخاذ احتياطات أخرى، أو في بعض الحالات إلى التوقف عن تناول أحد الأدوية. هذا ينطبق بشكل خاص على الأدوية التالية:</p><p dir="RTL">الليثيوم، وهو دواء يستعمل لعلاج بعض أنواع الأمراض النفسية.</p><p dir="RTL">الأدوية أو المواد التي قد تزيد من كمية البوتاسيوم في الدم. وتشمل هذه مكملات البوتاسيوم أو بدائل الملح المحتوية على البوتاسيوم، والأدوية الحافظة للبوتاسيوم والهيبارين.</p><p dir="RTL">الأدوية التي قد تقلل من كمية البوتاسيوم في الدم، مثل مدرات البول (أقراص الماء)، الستيرويدات القشرية، الملينات، كاربينوكسولون، أمفوتيريسين أو البنسيلين ج.</p><p dir="RTL">بعض المضادات الحيوية (مجموعة ريفاميسين)، وهو دواء يستعمل للوقاية من رفض العضو المزروع (سيكلوسبورين) أو الأدوية المضادة للفيروسات القهقرية والتي تستعمل لعلاج التهاب ڤيروس نقص المناعة المكتسبة/الإيدز (ريتوناڤير). هذه الأدوية قد تزيد من تأثير <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong>.</p><p dir="RTL">الأدوية التي قد تحفز الإصابة بتورساد دي بوينتس (ضفيرة النتوءات) (عدم انتظام نبضات القلب)، مثل أدوية اضطراب نظمية القلب (الأدوية المستعملة لعلاج مشاكل القلب) وبعض مضادات الذهان.</p><p dir="RTL">الأدوية التي قد تقلل من كمية الصوديوم في الدم، مثل مضادات الاكتئاب، مضادات الذهان، مضادات الصرع.</p><p dir="RTL">الأدوية التي تستعمل لعلاج النقرس، مثل ألوبيورينول، بروبينسيد، سلفينبيرازون.</p><p dir="RTL">فيتامين د العلاجي ومكملات الكالسيوم.</p><p dir="RTL">الأدوية التي تستعمل لعلاج داء السكري (العوامل التي يتم تناولها عن طريق الفم مثل الميتفورمين أو الإنسولين).</p><p dir="RTL">أدوية أخرى تستعمل لخفض ضغط الدم بما في ذلك ميثيل دوبا، مثبطات الإنزيم المحول للأنجيوتنسين (مثل إنالابريل، ليزينوبريل، وغيرها) أو أليسكرين.</p><p dir="RTL">الأدوية التي تستعمل لزيادة ضغط الدم، مثل نورأدرينالين أو أدرينالين.</p><p dir="RTL">ديجوكسين أو جلايكوسيدات الديجيتاليس الأخرى (الأدوية التي تستعمل لعلاج مشاكل القلب).</p><p dir="RTL">الأدوية التي قد تزيد من مستويات السكر في الدم، مثل ديازوكسيد أو حاصرات بيتا.</p><p dir="RTL">الأدوية التي تسبب سمية الخلايا (التي تستعمل لعلاج السرطان)، مثل ميثوتريكسيت أو سيكلوفوسفاميد.</p><p dir="RTL">مسكنات الألم مثل الأدوية غير الستيرويدية المضادة للالتهاب، بما في ذلك مثبطات إنزيم سيكلوأكسيجينيز-2 الإنتقائية و حمض أسيتيل ساليساليك (أكثر من 3 غرام).</p><p dir="RTL">الأدوية المرخية للعضلات، مثل توبوكيورارين.</p><p dir="RTL">الأدوية المضادة للكولين (أدوية تستعمل لعلاج اضطرابات متعددة مثل تقلصات المعدة والأمعاء، تشنج المثانة البولية، الربو، دوار الحركة، تشنجات عضلية، ومرض باركنسون وكعامل مساعد في التخدير).</p><p dir="RTL">أمانتادين (دواء يستعمل لعلاج مرض باركنسون ويستعمل أيضا لعلاج أو الوقاية من بعض الأمراض الناتجة عن الڤيروسات).</p><p dir="RTL">كولستيرامين وكوليستيبول (أدوية تستعمل بشكل أساسي لعلاج ارتفاع مستويات الدهون في الدم).</p><p dir="RTL">سيكلوسبورين، وهو دواء يستعمل في عملية زرع الأعضاء للوقاية من رفض العضو.</p><p dir="RTL">الكحول، الأقراص المنومة و أدوية التخدير (أدوية ذات تأثير منوم أو مسكن تستعمل خلال العمليات الجراحية).</p><p dir="RTL">وسط التباين الغني باليود (عوامل تستعمل خلال التصوير الإشعاعي).</p><p dir="RTL"><strong>تناول</strong><strong> </strong><strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>الطعام،</strong><strong> </strong><strong>الشراب</strong><strong> </strong><strong>والكحول</strong></p><p dir="RTL">تجنب تناول الكحول إلى أن تتحدث مع طبيبك. قد يسبب الكحول انخفاض كبير في ضغط الدم ​​و/أو زيادة خطر الشعور بالدوار أو الإغماء.</p><p dir="RTL"><strong>الحمل</strong><strong> </strong><strong>والرضاعة</strong><strong> </strong><strong>الطبيعية</strong></p><p dir="RTL"><strong>يجب</strong><strong> </strong><strong>أن</strong><strong> </strong><strong>تخبري</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>كنت</strong><strong> </strong><strong>تعتقدين</strong><strong> </strong><strong>بأنك</strong><strong> </strong><strong>حامل</strong><strong> (</strong><strong>أو</strong><strong> </strong><strong>قد</strong><strong> </strong><strong>تصبحين</strong><strong> </strong><strong>حامل</strong><strong>).</strong></p><p dir="RTL">سينصحك طبيبك عادة بالتوقف عن تناول <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong> قبل حصول الحمل أو فور معرفتك بأنك حامل، وسينصحك بتناول دواء آخر بدل من <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong>. لا يوصى بتناول <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong> في المرحلة المبكرة من الحمل، ويجب عدم تناوله إذا كان عمر الحمل يزيد عن 3 أشهر، حيث قد يسبب أذى خطير على الجنين إذا تم استعماله بعد الشهر الثالث من الحمل.</p><p dir="RTL"><strong>أخبري</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>كنت</strong><strong> </strong><strong>تُرضعين</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>على</strong><strong> </strong><strong>وشك</strong><strong> </strong><strong>بدء</strong><strong> </strong><strong>الرضاعة</strong><strong> </strong><strong>الطبيعية</strong><strong>.</strong></p><p dir="RTL">لا يوصى باستعمال <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong>&nbsp; للأمهات المرضعات، و قد يختار طبيبك علاج آخر لك إذا كنت ترغبين في الإرضاع، وخاصة إذا كان طفلك حديث الولادة، أو ولد قبل الأوان.</p><p dir="RTL"><strong>القيادة</strong><strong> </strong><strong>واستخدام</strong><strong> </strong><strong>الآلات</strong></p><p dir="RTL">قبل القيام بالقيادة، استخدام الأدوات أو تشغيل الآلات أو القيام بأي أنشطة أخرى تتطلب التركيز، تأكد من كيفية تأثير <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong> عليك. مثل العديد من الأدوية الأخرى التي تستعمل لعلاج ارتفاع ضغط الدم، قد يسبب <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong> أحيانا الشعور بالدوار ويؤثر على القدرة على التركيز.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائما تناول هذا الدواء تماما كما أخبرك طبيبك، سوف يساعد هذا في الحصول على أفضل النتائج وتقليل خطر التعرض للآثار الجانبية. تأكد من طبيبك أو الصيدلي إذا لم تكن متأكدا.</p><p dir="RTL">إن الأشخاص الذين يعانون من ارتفاع ضغط الدم غالبا لا يلاحظون أي من علامات هذه المشكلة. قد يشعر الكثيرون بأن وضعهم طبيعي جدا. وهذا يجعل الأمر أكثر أهمية بالنسبة لك للحفاظ على مراجعة طبيبك حتى لو كنت تشعر بأنك على ما يرام.</p><p dir="RTL">سيخبرك طبيبك تماما عن عدد أقراص <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong> الواجب تناولها. اعتمادا على كيفية استجابتك للعلاج، قد يقترح الطبيب جرعة أعلى أو أدنى.</p><p dir="RTL">&bull; الجرعة الموصى بها من <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong> هي قرص واحد يوميا.</p><p dir="RTL">&bull; لا تغيّر الجرعة أو تتوقف عن تناول الأقراص بدون استشارة طبيبك.</p><p dir="RTL">&bull; يجب تناول الدواء في نفس الوقت كل يوم، عادة في الصباح.</p><p dir="RTL">&bull; يمكن تناول <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong> مع أو بدون تناول الطعام.</p><p dir="RTL">&bull; تناول القرص مع شرب كوب من الماء.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>تناولت</strong><strong> </strong><strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong><strong> </strong><strong>أكثر</strong><strong> </strong><strong>مما</strong><strong> </strong><strong>يجب</strong></p><p dir="RTL">إذاعانيت من دوار حاد و/أو إغماء، استلق واتصل بطبيبك على الفور. إذا تناولت عن طريق الخطأ الكثير من الأقراص، اتصل مع طبيبك، الصيدلي أو المستشفى.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>نسيت</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>جرعة</strong><strong> </strong><strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong><strong>&nbsp; </strong></p><p dir="RTL">إذا نسيت تناول جرعة، تناولها فور تذكرك، لكن، إذا اقترب موعد تناول الجرعة التالية، لا تتناول الجرعة التي نسيتها. لا تتناول جرعة مضاعفة لتعويض الجرعة التي نسيتها.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>توقفت</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong></p><p dir="RTL">قد يسبب التوقف عن تناول العلاج باستعمال <strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong> ازدياد حالة ارتفاع ضغط الدم لديك سوءاً. لا تتوقف عن تناول الدواء ما لم يخبرك طبيبك بذلك.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>كان</strong><strong> </strong><strong>لديك</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>أسئلة</strong><strong> </strong><strong>أخرى</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>استعمال</strong><strong> </strong><strong>هذا</strong><strong> </strong><strong>الدواء،</strong><strong> </strong><strong>اسأل</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الصيدلي</strong>.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع جميع الأدوية، يمكن أن يسبب هذا الدوا آثار جانبية، على الرغم من عدم حصولها لدى الجميع.</p><p dir="RTL"><strong>قد</strong><strong> </strong><strong>تكون</strong><strong> </strong><strong>بعض</strong><strong> </strong><strong>الآثار</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>خطيرة</strong><strong> </strong><strong>وتحتاج</strong><strong> </strong><strong>إلى</strong><strong> </strong><strong>عناية</strong><strong> </strong><strong>طبية</strong><strong> </strong><strong>فورية</strong><strong>:</strong></p><p dir="RTL">يجب مراجعة طبيبك فورا إذا عانيت من أعراض الوذمة الوعائية، مثل:</p><p dir="RTL">- تورم الوجه، اللسان أو البلعوم.</p><p dir="RTL">- صعوبة في البلع.</p><p dir="RTL">- شرى وصعوبات في التنفس.</p><p dir="RTL">مرض حاد في الجلد الذي يسبب طفح، احمرار الجلد، تنفط الشفاه، العيون أو الفم، تقشر الجلد، حمى (تحلل نخري سام في البشرة).</p><p dir="RTL">ضعف الرؤية أو ألم في العيون نتيجة ارتفاع ضغط الدم (علامات محتملة لتجمع السوائل في الطبقة الوعائية للعين (الارتشاح المشيمي) أو الإصابة بجلوكوما الزاوية الحادة المغلقة).</p><p dir="RTL">حمى، التهاب الحلق، التهابات أكثر تكرارا (ندرة المحببات).</p><p dir="RTL">قصر حاد في النفس، حمى، الشعور بالضعف، و الارتباك (متلازمة الضائقة التنفسية الحادة).</p><p dir="RTL">تعد هذه الآثار الجانبية نادرة جدا أو تكرارها غير معروف.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>حصل</strong><strong> </strong><strong>لديك</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>من</strong><strong> </strong><strong>هذه</strong><strong> </strong><strong>الآثار،</strong><strong> </strong><strong>توقف</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong><strong> </strong><strong>واتصل</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>فورا</strong><strong>.</strong></p><p dir="RTL"><strong>تتضمن</strong><strong> </strong><strong>الآثار</strong><strong> </strong><strong>الجانبية</strong><strong>:</strong></p><p dir="RTL"><strong>غير</strong><strong> </strong><strong>شائعة</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>أو</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 100 </strong><strong>شخص</strong><strong>):</strong></p><p dir="RTL">&bull; سعال.</p><p dir="RTL">&bull; انخفاض ضغط الدم.</p><p dir="RTL">&bull; الشعور بالدوخة.</p><p dir="RTL">&bull; جفاف (مع ظهور أعراض العطش، جفاف الفم واللسان، قلة التبول، بول داكن اللون، جفاف الجلد).</p><p dir="RTL">&bull; آلام في العضلات.</p><p dir="RTL">&bull; الشعور بالتعب.</p><p dir="RTL">&bull; الشعور بوخز خفيف أو تنمل.</p><p dir="RTL">&bull; ضبابية الرؤية.</p><p dir="RTL">&bull; ضجيج (مثل هسهسة، طنين) في الأذنين.</p><p dir="RTL"><strong>نادرة</strong><strong> </strong><strong>جدا</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>أو</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 10000 </strong><strong>شخص</strong><strong>):</strong></p><p dir="RTL">&bull; الشعور بالدوار.</p><p dir="RTL">&bull; إسهال.</p><p dir="RTL">&bull; ألم في المفاصل.</p><p dir="RTL"><strong>غير</strong><strong> </strong><strong>معروفة</strong><strong> (</strong><strong>لا</strong><strong> </strong><strong>يمكن</strong><strong> </strong><strong>تقدير</strong><strong> </strong><strong>تكرار</strong><strong> </strong><strong>حدوثها</strong><strong> </strong><strong>من</strong><strong> </strong><strong>المعلومات</strong><strong> </strong><strong>المتوفرة</strong><strong>):</strong></p><p dir="RTL">&bull; صعوبة في التنفس.</p><p dir="RTL">&bull; انخفاض حاد في كمية البول المخرجة.</p><p dir="RTL">&bull; انخفاض مستوى الصوديوم في الدم (الذي قد يسبب الشعور بالتعب، الارتباك، نفضان في العضلات و/أو تشنجات في الحالات الحادة).</p><p dir="RTL">&bull; انخفاض مستوى البوتاسيوم في الدم (في بعض الأحيان يرافقه ضعف العضلات، تشنج العضلات، اضطرب نظمية القلب).</p><p dir="RTL">&bull; انخفاض مستوى الخلايا البيضاء في الدم (مع ظهور أعراض مثل الحمى، التهابات الجلد، التهاب الحلق أو تقرحات الفم نتيجة الالتهابات، الشعور بالضعف).</p><p dir="RTL">&bull; ارتفاع مستوى البيليروبين في الدم (الذي قد يسبب، في الحالات الحادة، إصفرار الجلد والعيون).</p><p dir="RTL">&bull; ارتفاع مستوى يوريا نيتروجين والكرياتينين في الدم (الذي قد يكون مؤشر على اضطراب وظائف الكلى).</p><p dir="RTL">&bull; زيادة مستوى حمض اليوريك في الدم (الذي قد يسبب، في الحالات الحادة، الإصابة بالنقرس).</p><p dir="RTL">&bull; الإغماء.</p><p dir="RTL"><strong>تم</strong><strong> </strong><strong>تسجيل</strong><strong> </strong><strong>حدوث</strong><strong> </strong><strong>الآثار</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>التالية</strong><strong> </strong><strong>عند</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>مستحضرات</strong><strong> </strong><strong>طبية</strong><strong> </strong><strong>تحتوي</strong><strong> </strong><strong>على</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>من</strong><strong> </strong><strong>ڤالسارتان</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>هيدروكلوروثيازيد</strong><strong> </strong><strong>لوحدها</strong><strong>.</strong></p><p dir="RTL"><strong><u>ڤالسارتان</u></strong></p><p dir="RTL"><strong>غير</strong><strong> </strong><strong>شائعة</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>أو</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 100 </strong><strong>شخص</strong><strong>):</strong></p><p dir="RTL">&bull; الشعور بالدوران.</p><p dir="RTL">&bull; ألم في البطن.</p><p dir="RTL"><strong>غير</strong><strong> </strong><strong>معروفة</strong><strong> (</strong><strong>لا</strong><strong> </strong><strong>يمكن</strong><strong> </strong><strong>تقدير</strong><strong> </strong><strong>تكرار</strong><strong> </strong><strong>حدوثها</strong><strong> </strong><strong>من</strong><strong> </strong><strong>المعلومات</strong><strong> </strong><strong>المتوفرة</strong><strong>):</strong></p><p dir="RTL">تنفط الجلد (أحد علامات التهاب الجلد الفقاعي).</p><p dir="RTL">طفح جلدي مع أو بدون الإصابة بالحكة التي يرفقها أحد العلامات والأعراض التالية: حمى، ألم المفاصل، ألم العضلات، تورم العقد الليمفاوية و/أو أعراض تشبه الإنفلونزا.</p><p dir="RTL">طفح ، بقع حمراء-أرجوانية، حمى، حكة (أعراض التهاب الأوعية الدموية).</p><p dir="RTL">انخفاض مستوى الصفيحات الدموية (أحيانا يرافقه نزيف غير معتاد أو ظهور الكدمات).</p><p dir="RTL">ارتفاع مستوى البوتاسيوم في الدم (أحيانا يرافقه تشنج العضلات، اضطراب نظمية القلب).</p><p dir="RTL">تفاعلات تحسسية (يرافقها ظهور أعراض مثل طفح، حكة، شرى، صعوبة في التنفس أو البلع، الشعور بالدوار).</p><p dir="RTL">تورم بشكل رئيسي في الوجه و الحلق، طفح، حكة.</p><p dir="RTL">ارتفاع قيم نتائج فحوصات وظائف الكلى.</p><p dir="RTL">انخفاض نسبة الهيموغلوبين ونسبة خلايا الدم الحمراء في الدم (قد يسبب كلاهما، في الحالات الحادة، فقر الدم).</p><p dir="RTL">قصور وظائف الكلى.</p><p dir="RTL">انخفاض مستوى الصوديوم في الدم (الذي قد يسبب الشعور بالتعب، الارتباك، نفضان في العضلات و/أو تشنجات في الحالات الحادة).</p><p dir="RTL"><strong><u>هيدروكلوروثيازيد</u></strong></p><p dir="RTL"><strong>شائعة</strong><strong> </strong><strong>جدا</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> </strong><strong>أكثر</strong><strong> </strong><strong>من</strong><strong> 1 </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 10 </strong><strong>أشخاص</strong><strong>):</strong></p><p dir="RTL">&bull; انخفاض مستوى البوتاسيوم في الدم.</p><p dir="RTL">&bull; زيادة نسبة الدهون في الدم.</p><p dir="RTL"><strong>شائعة</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>أو</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 10 </strong><strong>أشخاص</strong><strong>):</strong></p><p dir="RTL">&bull; انخفاض مستوى الصوديوم في الدم.</p><p dir="RTL">&bull; انخفاض مستوى المغنيسيوم في الدم.</p><p dir="RTL">&bull; ارتفاع مستوى حمض اليوريك في الدم.</p><p dir="RTL">&bull; طفح جلدي يسبب الحكة وغيرها من أنواع الطفح.</p><p dir="RTL">&bull; قلة الشهية.</p><p dir="RTL">&bull; الشعور بالغثيان وقيء بشكل معتدل.</p><p dir="RTL">&bull; الشعور بالدوار، الإغماء عند الوقوف.</p><p dir="RTL">&bull; عدم القدرة على الوصول إلى الانتصاب أو الحفاظ عليه.</p><p dir="RTL"><strong>نادرة</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>أو</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 1000 </strong><strong>شخص</strong><strong>):</strong></p><p dir="RTL">&bull; تورم وتنفط الجلد (نتيجة لازدياد التحسس لأشعة الشمس).</p><p dir="RTL">&bull; ارتفاع مستوى الكالسيوم في الدم.</p><p dir="RTL">&bull; ارتفاع مستوى السكر في الدم.</p><p dir="RTL">&bull; ظهور السكر في البول.</p><p dir="RTL">&bull; تدهور الأيض لدى مرضى السكري.</p><p dir="RTL">&bull; إمساك، إسهال، الشعور بعدم الراحة في المعدة أو الأمعاء، اضطرابات الكبد التي قد تحدث بالتزامن مع اصفرار الجلد و العيون.</p><p dir="RTL">&bull; عدم انتظام نبضات القلب.</p><p dir="RTL">&bull; صداع.</p><p dir="RTL">&bull; اضطرابات النوم.</p><p dir="RTL">&bull; مزاج حزين (الاكتئاب).</p><p dir="RTL">&bull; انخفاض مستوى الصفيحات الدموية (أحيانا يرافقه نزيف أو كدمات تحت الجلد).</p><p dir="RTL">&bull; الشعور بالدوار.</p><p dir="RTL">&bull; الشعور بوخز خفيف أو تنمل.</p><p dir="RTL">&bull; اضطراب الرؤية.</p><p dir="RTL"><strong>نادرة</strong><strong> </strong><strong>جدا</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>أو</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 10000 </strong><strong>شخص</strong><strong>):</strong></p><p dir="RTL">&bull; التهاب الأوعية الدموية مع ظهور أعراض مثل الطفح، ظهور بقع حمراء-أرجوانية، حمى (التهاب الأوعية الدموية).</p><p dir="RTL">&bull; طفح، حكة، شرى، صعوبة التنفس أو البلع، الشعور بالدوار (تفاعلات فرط التحسس).</p><p dir="RTL">&bull; طفح في الوجه، ألم في المفاصل، اضطراب العضلات، حمى (الذأب الحمامي).</p><p dir="RTL">&bull; ألم حاد أعلى المعدة (التهاب البنكرياس).</p><p dir="RTL">&bull; صعوبة في التنفس يرافقها حمى، سعال، أزيز تنفسي، ضيق في النفس (الضائقة التنفسية بما في ذلك التهاب رئوي و وذمة رئوية).</p><p dir="RTL">&bull; شحوب الجلد، الشعور بالتعب، ضيق في النفس، بول داكن اللون (فقر الدم الانحلالي).</p><p dir="RTL">&bull; حمى، التهاب الحلق أو تقرحات الفم نتيجة الالتهابات (نقص الكريات البيض).</p><p dir="RTL">&bull; الشعور بالارتباك، التعب، نفضان في العضلات وتشنج، سرعة التنفس (قلاء ناتج عن انخفاض مستوى الكلوريد في الدم).</p><p dir="RTL"><strong>غير</strong><strong> </strong><strong>معروفة</strong><strong> (</strong><strong>لا</strong><strong> </strong><strong>يمكن</strong><strong> </strong><strong>تقدير</strong><strong> </strong><strong>تكرار</strong><strong> </strong><strong>حدوثها</strong><strong> </strong><strong>من</strong><strong> </strong><strong>المعلومات</strong><strong> </strong><strong>المتوفرة</strong><strong>):</strong></p><p dir="RTL">&bull; الشعور بالضعف، ظهور الكدمات والتهابات متكررة (فقر الدم اللاتنسجي).</p><p dir="RTL">&bull; انخفاض حاد في كمية البول المخرجة (علامات محتملة لاضطراب أو قصور في وظائف الكلى).</p><p dir="RTL">&bull; طفح، احمرار الجلد، تنفط الشفاه، العيون أو الفم، تقشّر الجلد، حمى (علامات محتملة لحمامي متعددة الأشكال).</p><p dir="RTL">&bull; تشنج العضلات.</p><p dir="RTL">&bull; حمى.</p><p dir="RTL">&bull; الشعور بالضعف (الوهن).</p><p dir="RTL">&bull; سرطان الجلد والشفاه (سرطان الجلد غير الميلانيني).</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>عانيت</strong><strong> </strong><strong>من</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>آثار</strong><strong> </strong><strong>جانبية،</strong><strong> </strong><strong>تحدث</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>الصيدلي</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الممرض</strong><strong>. </strong><strong>هذا</strong><strong> </strong><strong>يتضمن</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>مذكورة</strong><strong>&nbsp; </strong><strong>في</strong><strong> </strong><strong>هذه</strong><strong> </strong><strong>النشرة</strong><strong>.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيدا عن متناول الأطفال و نظرهم.</p><p dir="RTL">لا تستعمل<strong> </strong><strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong><strong> </strong>بعد تاريخ انتهاء الصلاحية المذكورعلى الشريط و العلبة الخارجية.</p><p dir="RTL">تاريخ الانتهاء يشير إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL"><strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong><strong>&nbsp; </strong>أقراص: يحفظ&nbsp; بدرجة حرارة دون 30 &deg;م.</p><p dir="RTL">يجب أن لا يتم التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. وسوف تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المواد الفعالة هي ڤالسارتان وهيدروكلوروثيازيد.</p><p dir="RTL">المكونات الأخرى هي ميكروكريستالين سيليلوز، كروسكارميلوز الصوديوم، بوفيدون، ثاني أكسيد السيليكون الغروي، ستيرات المغنيسيوم، أوبادري أبيض، لون FD &amp; C الأحمر # 40، لون FD &amp; C الأزرق # 1، ماء نقي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong><strong> 80/12.5 </strong><strong>ملغم</strong><strong>:</strong> أقراص مغلفة مستطيلة الشكل محدبة الوجهين، ذات لون بنفسجي فاتح، محفور على أحد الأوجه A1، معبأة في أشرطة ألومنيوم/ألومنيوم، معدة للاستعمال عن طريق الفم.</p><p dir="RTL"><strong>حجم</strong><strong> </strong><strong>العبوة</strong><strong>:</strong> 03 قرص مغلف (01 أقراص/شريط، 3 أشرطة/علبة).</p><p dir="RTL"><strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong><strong> 160/12.5 </strong><strong>ملغم</strong><strong>:</strong> أقراص مغلفة مستطيلة الشكل محدبة الوجهين، ذات لون أرجواني، محفور على أحد الأوجه H21، معبأة في أشرطة ألومنيوم/ألومنيوم، معدة للاستعمال عن طريق الفم.</p><p dir="RTL"><strong>حجم</strong><strong> </strong><strong>العبوة</strong><strong>:</strong> 03 قرص مغلف (01 أقراص/شريط، 3 أشرطة/علبة).</p><p dir="RTL"><strong>أڤيسك</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>إتش</strong><strong> </strong><strong>سي</strong><strong> </strong><strong>تي</strong><strong> 160/25 </strong><strong>ملغم</strong><strong>:</strong> أقراص مغلفة مستطيلة الشكل محدبة الوجهين، ذات لون بنفسجي فاتح، محفور على أحد الأوجه H17، معبأة في أشرطة ألومنيوم/ألومنيوم، معدة للاستعمال عن طريق الفم.</p><p dir="RTL"><strong>حجم</strong><strong> </strong><strong>العبوة</strong><strong>:</strong> 03 قرص مغلف (01 أقراص/شريط، 3 أشرطة/علبة).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مدينة الدواء للصناعات الدوائية - المملكة العربية السعودية.</p><p dir="RTL">المدينة الصناعية الأولى، المرحلة الخامسة، جدة - المملكة العربية السعودية.</p><p dir="RTL">هاتف: 00966920003288</p><p dir="RTL">جوال: 00966555786968</p><p dir="RTL">ص.ب: 4072 - جدة 22429</p><p dir="RTL">بريد الكتروني: info@medcitypharma.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            08/2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Avysk® HCT 80/12.5 mg film-coated tablets.
Avysk® HCT 160/12.5 mg film-coated tablets.
Avysk® HCT 160/25 mg film-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Avyska® HCT 80/12.5 mg Tablets: Each tablet contains 80 mg valsartan and 12.5 mg hydrochlorothiazide.
Avyska® HCT 160/12.5 mg Tablets: Each tablet contains 160 mg valsartan and 12.5 mg hydrochlorothiazide.
Avyska® HCT 160/25 mg Tablets: Each tablet contains 160 mg valsartan and 25 mg hydrochlorothiazide. 
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film Coated Tablets.

Avyska® HCT 80/12.5 mg: Light violet oblong normal biconvex film coated tablets, engraved with A1 on one face and plain on the other, presented in Alu/Alu blisters, intended for oral use.
Avyska® HCT 160/12.5 mg: Purple oblong deep biconvex film coated tablets, engraved with H21 on one face and and plain on the other face, presented in Alu/Alu blisters, intended for oral use.
Avyska® HCT 160/25 mg: Light violet oblong deep biconvex film coated tablets, engraved with H17 on one face and plain on the other face, presented in Alu/Alu blisters, intended for oral use.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of essential hypertension in adults.</p><p><strong>Avyska<sup>&reg;</sup> HCT </strong>fixed-dose combination is indicated in patients whose blood pressure is not adequately controlled on valsartan or hydrochlorothiazide monotherapy.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Posology</u></strong></p><p>The recommended dose of <strong>Avyska<sup>&reg;</sup> HCT </strong>80/12.5mg or 160/12.5mg or 160/25mg is one film-coated tablet once daily. Dose titration with the individual components is recommended. In each case, up- titration of individual components to the next dose should be followed in order to reduce the risk of hypotension and other adverse events.</p><p>When clinically appropriate direct change from monotherapy to the fixed combination may be considered in patients whose blood pressure is not adequately controlled on valsartan or hydrochlorothiazide monotherapy, provided the recommended dose titration sequence for the individual components is followed.</p><p>The clinical response to <strong>Avyska<sup>&reg;</sup> HCT <sup>&reg;</sup></strong> should be evaluated after initiating therapy and if blood pressure remains uncontrolled, the dose may be increased by increasing either one of the components to a maximum dose of Valsartan/hydrochlorothiazide 320 mg/25 mg.</p><p>The antihypertensive effect is substantially present within 2 weeks.</p><p>In most patients, maximal effects are observed within 4 weeks. However, in some patients, 4-8 weeks treatment may be required. This should be taken into account during dose-titration.</p><p><em><u>Method of administration</u></em></p><p><strong>Avyska<sup>&reg;</sup> HCT </strong>can be taken with or without food and should be administered with water.</p><p><strong><em><u>Special populations</u></em></strong></p><p><strong><em>Patients with renal impairment</em></strong></p><p>No dose adjustment is required for patients with mild to moderate renal impairment (Glomerular Filtration Rate (GFR) &ge; 30 ml/min). Due to the hydrochlorothiazide component, <strong>Avyska<sup>&reg;</sup> HCT</strong> is contraindicated in patients with severe renal impairment (GFR &lt; 30 mL/min) and anuria (see sections 4.3, 4.4 and 5.2).</p><p><strong><em>Patients with hepatic impairment</em></strong></p><p>In patients with mild to moderate hepatic impairment without cholestasis the dose of valsartan should not exceed 80 mg (see section 4.4). No adjustment of the hydrochlorothiazide dose is required for patients with mild to moderate hepatic impairment. Due to the valsartan component, <strong>Avyska<sup>&reg;</sup> HCT</strong> is contraindicated in patients with severe hepatic impairment or with biliary cirrhosis and cholestasis (see sections 4.3, 4.4 and 5.2).</p><p><strong><em>Older people</em></strong></p><p>No dose adjustment is required in elderly patients.</p><p><strong><em>Paediatric patients</em></strong></p><p><strong>Avyska<sup>&reg;</sup> HCT</strong> is not recommended for use in children below the age of 18 years due to a lack of data on safety and efficacy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
•	Hypersensitivity to active substances, other sulfonamide-derived medicinal products or to any of the excipients listed in section 6.1.
•	Second and third trimester of pregnancy (section 4.4 and 4.6).
•	Severe hepatic impairment, biliary cirrhosis and cholestasis.
•	Severe renal impairment (creatinine clearance < 30 ml/min), anuria.
•	Refractory hypokalaemia, hyponatraemia, hypercalcaemia, and symptomatic hyperuricaemia.
•	Concomitant use of Avyska® HCT with aliskiren containing products in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73m2) (see sections 4.5 and 5.1).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Serum electrolyte changes</u></strong></p><p><strong><em>Valsartan</em></strong></p><p>Concomitant use with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other agents that may increase potassium levels (heparin, etc.) is not recommended. Monitoring of potassium should be undertaken as appropriate.</p><p><strong><em>Hydrochlorothiazide</em></strong></p><p>Hypokalaemia has been reported under treatment with thiazide diuretics, including hydrochlorothiazide. Frequent monitoring of serum potassium is recommended.</p><p>Treatment with thiazide diuretics, including hydrochlorothiazide, has been associated with hyponatraemia and hypochloraemic alkalosis. Thiazides, including hydrochlorothiazide, increase the urinary excretion of magnesium, which may result in hypomagnesaemia. Calcium excretion is decreased by thiazide diuretics. This may result in hypercalcaemia.</p><p>As for any patient receiving diuretic therapy, periodic determination of serum electrolytes should be performed at appropriate intervals.</p><p><strong><u>Sodium and/or volume-depleted patients</u></strong></p><p>Patients receiving thiazide diuretics, including hydrochlorothiazide, should be observed for clinical signs of fluid or electrolyte imbalance.</p><p>In severely sodium-depleted and/or volume-depleted patients, such as those receiving high doses of diuretics, symptomatic hypotension may occur in rare cases after initiation of therapy with valsartan/hydrochlorothiazide. Sodium and/or volume depletion should be corrected before starting treatment with <strong>Avyska<sup>&reg;</sup> HCT</strong>.</p><p><strong><u>Patients with severe chronic heart failure or other conditions with stimulation of the renin-angiotensin-aldosterone-system</u></strong></p><p>In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure), treatment with angiotensin converting enzyme inhibitors has been associated with oliguria and/or progressive azotaemia, and in rare cases with acute renal failure and/or death. Evaluation of patients with heart failure or post-myocardial infarction should always include assessment of renal function. The use of valsartan/hydrochlorothiazide in patients with severe chronic heart failure has not been established.</p><p>Hence it cannot be excluded that because of the inhibition of the renin-angiotensin-aldosterone system the application of valsartan/hydrochlorothiazide as well may be associated with impairment of the renal function. <strong>Avyska<sup>&reg;</sup> HCT </strong>should not be used in these patients.</p><p><strong><u>Renal artery stenosis</u></strong></p><p><strong>Avyska<sup>&reg;</sup> HCT </strong>should not be used to treat hypertension in patients with unilateral or bilateral renal artery stenosis or stenosis of the artery to a solitary kidney, since blood urea and serum creatinine may increase in such patients.</p><p><strong><u>Primary hyperaldosteronism</u></strong></p><p>Patients with primary hyperaldosteronism should not be treated with <strong>Avyska<sup>&reg;</sup> HCT</strong> as their renin-angiotensin system is not activated.</p><p><strong><u>Aortic and mitral valve stenosis, hypertrophic obstructive cardiomyopathy</u></strong></p><p>As with all other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or hypertrophic obstructive cardiomyopathy (HOCM).</p><p><strong><u>Renal impairment</u></strong></p><p>No dosage adjustment is required for patients with renal impairment with a creatinine clearance &ge;30 ml/min (see section 4.2). Periodic monitoring of serum potassium, creatinine and uric acid levels is recommended when <strong>Avyska<sup>&reg;</sup> HCT </strong>is used in patients with renal impairment.</p><p><strong><u>Kidney transplantation</u></strong></p><p>There is currently no experience on the safe use of valsartan/hydrochlorothiazide in patients who have recently undergone kidney transplantation.</p><p><strong><u>Hepatic impairment</u></strong></p><p>In patients with mild to moderate hepatic impairment without cholestasis<em>,&nbsp;</em><strong>Avyska<sup>&reg;</sup> HCT </strong>should be used with caution (see sections 4.2 and 5.2)<em>.</em>&nbsp;Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.</p><p><strong><u>History of angioedema</u></strong></p><p>Angioedema, including swelling of the larynx and glottis, causing airway obstruction and/or swelling of the face, lips, pharynx, and/or tongue has been reported in patients treated with valsartan; some of these patients previously experienced angioedema with other drugs including ACE inhibitors. <strong>Avyska<sup>&reg;</sup> HCT </strong>should be immediately discontinued in patients who develop angioedema, and <strong>Avyska<sup>&reg;</sup> HCT </strong>should not be re-administered (see section 4.8).</p><p><strong><u>Systemic lupus erythematosus</u></strong></p><p>Thiazide diuretics, including hydrochlorothiazide, have been reported to exacerbate or activate systemic lupus erythematosus.</p><p><strong><u>Other metabolic disturbances</u></strong></p><p>Thiazide diuretics, including hydrochlorothiazide, may alter glucose tolerance and raise serum levels of cholesterol, triglycerides and uric acid. In diabetic patients dosage adjustments of insulin or oral hypoglycaemic agents may be required.</p><p>Thiazides may reduce urinary calcium excretion and cause an intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Marked hypercalcaemia may be evidence of underlying hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function.</p><p><strong><u>Photosensitivity</u></strong></p><p>Cases of photosensitivity reactions have been reported with thiazide diuretics (see section 4.8). If photosensitivity reaction occurs during treatment, it is recommended to stop the treatment. If a re-administration of the diuretic is deemed necessary, it is recommended to protect exposed areas to the sun or to artificial UVA.</p><p><strong><u>Pregnancy</u></strong></p><p>Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. Unless continued AIIRAs therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p><p><strong><u>General</u></strong></p><p>Caution should be exercised in patients who have shown prior hypersensitivity to other angiotensin II receptor antagonists. Hypersensitivity reactions to hydrochlorothiazide are more likely in patients with allergy and asthma.</p><p><strong><u>Choroidal effusion, acute myopia and secondary acute Angle-Closure Glaucoma</u></strong></p><p>Hydrochlorothiazide, a sulfonamide, has been associated with an idiosyncratic reaction resulting in choroidal effusion with visual filed defect, acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to week of a drug initiation. Untreated acute-angle closure glaucoma can lead to permanent vision loss.</p><p>The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatment may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle closure glaucoma may include a history of sulfonamide or penicillin allergy.</p><p><strong><u>Dual Blockade of the Renin-Angiotensin-Aldosterone System (RAAS)</u></strong></p><p>There is evidence that the concomitant use of ACE inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia, and decreased renal function (including acute renal failure). Dual blockade of the RAAS through the combined use of ACE inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see section 4.5 and 5.1).</p><p>If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure. ACE inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p><strong><u>Non-melanoma skin cancer</u></strong></p><p>An increased risk of non-melanoma skin cancer (NMSC) [basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)] with increasing cumulative dose of hydrochlorothiazide exposure has been observed in two epidemiological studies based on the Danish National Cancer Registry. Photosensitising actions of hydrochlorothiazide could act as a possible mechanism for NMSC.</p><p>Patients taking hydrochlorothiazide should be informed of the risk of NMSC and advised to regularly check their skin for any new lesions and promptly report any suspicious skin lesions. Possible preventive measures such as limited exposure to sunlight and UV rays and, in case of exposure, adequate protection should be advised to the patients in order to minimize the risk of skin cancer. Suspicious skin lesions should be promptly examined potentially including histological examinations of biopsies. The use of hydrochlorothiazide may also need to be reconsidered in patients who have experienced previous NMSC (see also section 4.8).</p><p><strong><u>Acute respiratory toxicity</u></strong></p><p>Very rare severe cases of acute respiratory toxicity, including acute respiratory distress syndrome (ARDS), have been reported after taking hydrochlorothiazide. Pulmonary oedema typically develops within minutes to hours after hydrochlorothiazide intake. At the onset, symptoms include dyspnoea, fever, pulmonary deterioration and hypotension. If diagnosis of ARDS is suspected, <strong>Avyska<sup>&reg;</sup> HCT</strong> should be withdrawn, and appropriate treatment given. Hydrochlorothiazide should not be administered to patients who previously experienced ARDS following hydrochlorothiazide intake.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Interactions related to both valsartan and hydrochlorothiazide</u></p><p><em><u>Concomitant use not recommended</u></em></p><p><em>Lithium</em></p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, angiontensin II receptor antagonist or thiazides, including hydrochlorothiazide. Since renal clearance of lithium is reduced by thiazides, the risk of lithium toxicity may presumably be increased further with <strong>Avyska<sup>&reg;</sup> HCT</strong>. If the combination proves necessary, a careful monitoring of serum lithium levels is recommended.</p><p><em><u>Concomitant use requiring caution</u></em></p><p><em>Other antihypertensive agents</em></p><p><strong>Avyska<sup>&reg;</sup> HCT </strong>may increase the effects of other agents with antihypertensive properties (e.g. guanethidine, methyldopa, vasodilators, ACEI, ARBs, beta-blockers, calcium channel blockers and DRIs).</p><p><em>Pressor amines</em>&nbsp;(e.g. noradrenaline, adrenaline)</p><p>Possible decreased response to pressor amines. The clinical significance of this effect is uncertain and not sufficient to preclude their use.</p><p><em>Non-steroidal anti-inflammatory medicines (NSAIDs), including selective&nbsp;</em>COX<em>-2 inhibitors, acetylsalicylic acid (&gt;3 g/day), and non-selective NSAIDs.</em></p><p>NSAIDS can attenuate the antihypertensive effect of both angiotensin II antagonists and hydrochlorothiazide when administered simultaneously. Furthermore, concomitant use of <strong>Avyska<sup>&reg;</sup> HCT </strong>and NSAIDs may lead to worsening of renal function and an increase in serum potassium. Therefore, monitoring of renal function at the beginning of the treatment is recommended, as well as adequate hydration of the patient.</p><p><u>Interactions related to valsartan</u></p><p><em><u>Dual blockade of the Renin-Angiotensin-Aldosterone System (RAAS) with ARBs, ACEIs, or aliskiren</u></em></p><p>Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of s single RAAS-acting agent (see section 4.3, 4.4 and 5.1).</p><p><em><u>Concomitant use not recommended</u></em></p><p><em>Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may increase potassium levels.</em></p><p>If a medicinal product that affects potassium levels is considered necessary in combination with valsartan, monitoring of potassium plasma levels is advised.</p><p><em><u>Transporters</u></em></p><p>In vitro data indicates that valsartan is a substrate of the hepatic uptake transporter OATP1B1/OATP1B3 and the hepatic efflux transporter MRP2. The clinical relevance of this finding is unknown. Co-administration of inhibitors of the uptake transporter (eg. rifampin, ciclosporin) or efflux transporter (eg. ritonavir) may increase the systemic exposure to valsartan. Exercise appropriate care when initiating or ending concomitant treatment with such drugs.</p><p><em>No interaction</em></p><p>In drug interaction studies with valsartan, no interactions of clinical significance have been found with valsartan or any of the following substances: cimetidine, warfarin, furosemide, digoxin, atenolol, indomethacin, hydrochlorothiazide, amlodipine, glibenclamide. Digoxin and indomethacin could interact with the hydrochlorothiazide component of <strong>Avyska<sup>&reg;</sup> HCT</strong> (see interactions related to hydrochlorothiazide).</p><p><u>Interactions related to hydrochlorothiazide</u></p><p><em><u>Concomitant use requiring caution</u></em></p><p><em>Medicinal products affecting serum potassium level</em></p><p>The hypokalaemic effect of hydrochlorothiazide may be increased by concomitant administration of kaliuretic diuretics, corticosteroids, laxatives, ACTH, amphotericin, carbenoxolone, penicillin G, salicylic acid and derivatives.</p><p>If these medicinal products are to be prescribed with the hydrochlorothiazide-valsartan combination, monitoring of potassium plasma levels is advised (see section 4.4).</p><p><em>Medicinal products that could induce torsades de pointes</em></p><p>Due to the risk of hypokalaemia, hydrochlorothiazide should be administered with caution when associated with medicinal products that could induce torsades de pointes, in particular Class Ia and Class III antiarrhythmics and some antipsychotics.</p><p><em>Medicinal products affecting serum sodium level</em></p><p>The hyponatraemic effect of diuretics may be intensified by concomitant administration of drugs such as antidepressants, antipsychotics, antiepileptics, etc. Caution is advised in long-term administration of these drugs.</p><p><em>Digitalis glycosides</em></p><p>Thiazide-induced hypokalaemia or hypomagnesaemia may occur as undesirable effects favouring the onset of digitalis-induced cardiac arrhythmias (see section 4.4).</p><p><em>Calcium salts and vitamin D</em></p><p>Administration of thiazide diuretics, including hydrochlorothiazide, with vitamin D or with calcium salts may potentiate the rise in serum calcium. Concomitant use of thiazide type diuretics with calcium salts may cause hypercalcaemia in patients pre-disposed for hypercalcaemia (e.g. hyperparathyroidism, malignancy or vitamin-D-mediated conditions) by increasing tubular calcium reabsorption.</p><p><em>Antidiabetic agents</em>&nbsp;(oral agents and insulin)</p><p>Thiazides may alter glucose tolerance. Dose adjustment of the antidiabetic medicinal product may be necessary.</p><p>Metformin should be used with caution because of the risk of lactic acidosis induced by possible functional renal failure linked to hydrochlorothiazide.</p><p><em>Beta blockers and diazoxide</em></p><p>Concomitant use of thiazide diuretics, including hydrochlorothiazide, with beta blockers may increase the risk of hyperglycaemia. Thiazide diuretics, including hydrochlorothiazide, may enhance the hyperglycaemic effect of diazoxide.</p><p><em>Medicinal products used in the treatment of gout</em>&nbsp;(probenecid, sulfinpyrazone and allopurinol)</p><p>Dose adjustment of uricosuric medications may be necessary as hydrochlorothiazide may raise the level of serum uric acid. Increase of dosage of probenecid or sulfinpyrazone may be necessary. Co-administration of thiazide diuretics, including hydrochlorothiazide, may increase the incidence of hypersensitivity reactions to allopurinol.</p><p><em>Anticholinergic agents</em>&nbsp;<em>and other medicinal products affecting gastric motility</em></p><p>The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents (e.g. atropine, biperiden), apparently due to a decrease in gastrointestinal motility and the stomach emptying rate. Conversely, it is anticipated that prokinetic drugs such as cisapride may decrease the bioavailability of thiazide-type diuretics.</p><p><em>Amantadine</em></p><p>Thiazides, including hydrochlorothiazide, may increase the risk of adverse effects caused by amantadine.</p><p><em>Ion exchange resins</em></p><p>Absorption of thiazide diuretics, including hydrochlorothiazide, is decreased by cholestyramine or colestipol. This could result in sub-therapeutic effects of thiazide diuretics. However, staggering the dosage of hydrochlorothiazide and resin such that hydrochlorothiazide is administered at least 4 h before or 4-6 h after the administration of resins would potentially minimise the interaction.</p><p><em>Cytotoxic agents</em></p><p>Thiazides, including hydrochlorothiazide, may reduce renal excretion of cytotoxic agents (e.g. cyclophosamide, methotrexate) and potentiate their myelosuppressive effects.</p><p><em>Non-depolarising skeletal muscle relaxants</em>&nbsp;(e.g. tubocurarine)</p><p>Thiazides, including hydrochlorothiazide, potentiate the action of skeletal muscle relaxants such as curare derivatives.</p><p><em>Ciclosporin</em></p><p>Concomitant treatment with ciclosporin may increase the risk of hyperuricaemia and gout-type complications.</p><p><em>Alcohol, barbiturates or narcotics</em></p><p>Concomitant administration of thiazide diuretics with substances that also have a blood pressure lowering effect (e.g. by reducing sympathetic central nervous system activity or direct vasodilatation activity) may potentiate orthostatic hypotension.</p><p><em>Methyldopa</em></p><p>There have been isolated reports of haemolytic anaemia in patients receiving concomitant treatment with methyldopa and hydrochlorothiazide.</p><p><em>Iodine contrast media</em></p><p>In case of diuretic-induced dehydration, there is an increased risk of acute renal failure, especially with high doses of the iodine product. Patients should be rehydrated before the administration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Pregnancy</u></em></p><p>Valsartan</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p>The use of Angiotensin II Receptor Antagonists (AIIRAs) is not recommended during first trimester of pregnancy (see section 4.4). The use of AIIRAs is contra-indicated during the second and third trimester of pregnancy (see sections 4.3 and 4.4).</p></td></tr></tbody></table><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor Inhibitors (AIIRAs), similar risks may exist for this class of drugs. Unless continued AIIRAs therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately and, if appropriate, alternative therapy should be started.</p><p>AIIRAs therapy exposure during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see also section 5.3).</p><p>Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.</p><p>Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see also section 4.3 and 4.4).</p><p>Hydrochlorothiazide</p><p>There is limited experience with hydrochlorothiazide during pregnancy, especially during the first trimester. Animal studies are insufficient. Hydrochlorothiazide crosses the placenta. Based on the pharmacological mechanism of action of hydrochlorothiazide its use during the second and third trimester may compromise foeto-placental perfusion and may cause foetal and neonatal effects like icterus, disturbance of electrolyte balance and thrombocytopenia.</p><p><em><u>Breast-feeding</u></em></p><p>No information is available regarding the use of valsartan during breastfeeding. Hydrochlorothiazide is excreted in human milk. Therefore the use of <strong>Avyska<sup>&reg;</sup> HCT</strong> during breast feeding is not recommended. Alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effect of valsartan/hydrochlorothiazide, on the ability to drive and use machines have been performed. When driving vehicles or operating machines it should be taken into account that occasionally dizziness or weariness may occur.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse drug reactions reported in clinical trials and laboratory findings occurring more frequently with valsartan plus hydrochlorothiazide versus placebo and individual postmarketing reports are presented below according to system organ class. Adverse drug reactions known to occur with each component given individually but which have not been seen in clinical trials may occur during treatment with valsartan/ hydrochlorothiazide.</p><p><strong><u>Adverse Drug Reactions</u></strong></p><p>Adverse drug reactions are ranked by frequency, the most frequent first, using the following convention: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to<em>&nbsp;&lt;&nbsp;</em>1/1,000); very rare (&lt; 1/10,000); not known (frequency cannot be estimated from the available data).</p><p>Within each frequency grouping, adverse drug reactions are ranked in order of decreasing seriousness.</p><p><u>&nbsp;</u></p><p><u>Table 1. Frequency of adverse reactions with valsartan/hydrochlorothiazide</u></p><table border="0" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Dehydration</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td colspan="2" style="vertical-align:top"><p>Dizziness</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td colspan="2" style="vertical-align:top"><p>Syncope</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Vision blurred</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Tinnitus</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Hypotension</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Cough</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td colspan="2" style="vertical-align:top"><p>Non cardiogenic pulmonary oedema</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td colspan="2" style="vertical-align:top"><p>Diarrhoea</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td colspan="2" style="vertical-align:top"><p>Arthralgia</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td colspan="2" style="vertical-align:top"><p>Impaired renal function</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Fatigue</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td colspan="2" style="vertical-align:top"><p>Serum uric acid increased, Serum bilirubin and Serum creatinine increased, Hypokalaemia, Hyponatraemia, Elevation of Blood Urea Nitrogen, Neutropenia</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>Additional information on the individual components</u></p><p>Adverse reactions previously reported with one of the individual components may be potential undesirable effects with valsartan/hydrochlorothiazide as well, even if not observed in clinical trials or during post-marketing period.</p><p><u>&nbsp;</u></p><p><u>Table 2. Frequency of adverse reactions with valsartan</u></p><table border="0" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Decrease in haemoglobin, decrease in haematocrit, thrombocytopenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Other hypersensitivity/allergic reactions including serum sickness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Increase of serum potassium, hyponatraemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Vasculitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Abdominal pain</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Elevation of liver function values</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Angioedema, dermatitis bullous, rash, pruritus</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Renal failure</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>Table 3. Frequency of adverse reactions with hydrochorothiazide</u></p><p>Hydrochlorothiazide has been extensively prescribed for many years, frequently in higher doses than those administered with valsartan/hydrochlorothiazide. The following adverse reactions have been reported in patients treated with monotherapy of thiazide diuretics, including hydrochlorothiazide:</p><table border="0" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Neoplasms benign, malignant and unspecified (incl. cysts and polyps)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Non-melanoma skin cancer (Basal cell carcinoma and Squamous cell carcinoma)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Thrombocytopenia sometimes with purpura</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Agranulocytosis, leucopenia, haemolytic anaemia, bone marrow failure</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Aplastic anemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Hypokalaemia, blood lipids increased (mainly at higher doses)</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hyponatraemia, hypomagnesaemia, hyperuricaemia</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hypercalcaemia, hyperglycaemia, glycosuria and worsening of diabetic metabolic state</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Hypochloraemic alkalosis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Depression, sleep disturbances</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Headache, dizziness, paraesthesia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Visual impairment</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Choroidal effusion, acute angle-closure glaucoma</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Cardiac arrhythmias</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Postural hypotension</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Acute respiratory distress syndrome (ARDS) (see section 4.4), respiratory distress including pneumonitis and pulmonary oedema</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Loss of appetite, mild nausea and vomiting</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Constipation, gastrointestinal discomfort, diarrhea</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Pancreatitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Intrahepatic cholestasis or jaundice</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Renal dysfunction, acute renal failure</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Urticaria and other forms of rash</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Photosensitisation</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Necrotising vasculitis and toxic epidermal necrolysis, cutaneous lupus erythematosus-like reactions, reactivation of cutaneous lupus erythematosus</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Erythema multiforme</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Pyrexia, asthenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Muscle spasm</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Impotence</p></td></tr></tbody></table><p><u>Description of selected adverse reactions</u></p><p>Non-melanoma skin cancer: based on available data from epidemiological studies, cumulative dose dependent association between hydrochlorothiazide and NMSC has been observed (see also sections 4.4 and 5.1).</p><p><strong>&nbsp;</strong></p><p><strong>To report any side effect (s):</strong></p><p><strong>&bull;Saudi Arabia:</strong></p><p>The National Pharmacovigilance Center (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/</p><p><strong>&bull;Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Symptoms</u></em></p><p>Overdose with valsartan may result in marked hypotension, which could lead to depressed level of consciousness, circulatory collapse and/or shock. In addition, the following signs and symptoms may occur due to an overdose of the hydrochlorothiazide component: nausea, somnolence, hypovolaemia, and electrolyte disturbances associated with cardiac arrhythmias and muscle spasms.</p><p><em><u>Treatment</u></em></p><p>The therapeutic measures depend on the time of ingestion and the type and severity of the symptoms, stabilisation of the circulatory condition being of prime importance.</p><p>If hypotension occurs, the patient should be placed in the supine position and salt and volume supplementation should be given rapidly.</p><p>Valsartan cannot be eliminated by means of haemodialysis because of its strong plasma binding behaviour whereas clearance of hydrochlorothiazide will be achieved by dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Angiotensin II antagonists and diuretics, valsartan and diuretics; ATC code: C09D A03</p><p><em><u>Valsartan/hydrochlorothiazide</u></em></p><p><u>Valsartan/hydrochlorothiazide 80/12.5 mg Tablets only:</u></p><p>In a double-blind, randomised, active-controlled trial in patients not adequately controlled on hydrochlorothiazide 12.5 mg, significantly greater mean systolic/diastolic BP reductions were observed with the combination of valsartan/hydrochlorothiazide 80/12.5 mg (14.9/11.3 mmHg) compared to hydrochlorothiazide 12.5 mg (5.2/2.9 mmHg) and hydrochlorothiazide 25 mg (6.8/5.7 mmHg). In addition, a significantly greater percentage of patients responded (diastolic BP &lt;90 mmHg or reduction &ge;10 mmHg) with valsartan/hydrochlorothiazide 80/12.5 mg (60%) compared to hydrochlorothiazide 12.5 mg (25%) and hydrochlorothiazide 25 mg (27%).</p><p>In a double-blind, randomised, active-controlled trial in patients not adequately controlled on valsartan 80 mg, significantly greater mean systolic/diastolic BP reductions were observed with the combination of valsartan/hydrochlorothiazide 80/12.5 mg (9.8/8.2 mmHg) compared to valsartan 80 mg (3.9/5.1 mmHg) and valsartan 160 mg (6.5/6.2 mmHg). In addition, a significantly greater percentage of patients responded (diastolic BP &lt;90 mmHg or reduction &ge;10 mmHg) with valsartan/hydrochlorothiazide 80/12.5 mg (51%) compared to valsartan 80 mg (36%) and valsartan 160 mg (37%).</p><p>In a double-blind, randomised, placebo-controlled, factorial design trial comparing various dose combinations of valsartan/hydrochlorothiazide to their respective components, significantly greater mean systolic/diastolic BP reductions were observed with the combination of valsartan/hydrochlorothiazide 80/12.5 mg (16.5/11.8 mmHg) compared to placebo (1.9/4.1 mmHg) and both hydrochlorothiazide 12.5 mg (7.3/7.2 mmHg) and valsartan 80 mg (8.8/8.6 mmHg). In addition, a significantly greater percentage of patients responded (diastolic BP &lt;90 mmHg or reduction &ge;10 mmHg) with valsartan/hydrochlorothiazide 80/12.5 mg (64%) compared to placebo (29%) and hydrochlorothiazide (41%).</p><p><u>Valsartan/hydrochlorothiazide 160/12.5 mg and 160/25mg Tablets only:</u></p><p>In a double-blind, randomised, active-controlled trial in patients not adequately controlled on hydrochlorothiazide 12.5 mg, significantly greater mean systolic/diastolic BP reductions were observed with the combination of valsartan/ hydrochlorothiazide 160/12.5 mg (12.4/7.5 mmHg) compared to hydrochlorothiazide 25 mg (5.6/2.1 mmHg). In addition, a significantly greater percentage of patients responded (BP &lt;140/90 mmHg or SBP reduction &ge;20 mmHg or DBP reduction &ge;10 mmHg) with valsartan/hydrochlorothiazide 160/12.5 mg (50%) compared to hydrochlorothiazide 25 mg (25%).</p><p>In a double-blind, randomised, active-controlled trial in patients not adequately controlled on valsartan 160 mg, significantly greater mean systolic/diastolic BP reductions were observed with both the combination of valsartan/hydrochlorothiazide 160/25 mg (14.6/11.9 mmHg) and valsartan/hydrochlorothiazide 160/12.5 mg (12.4/10.4 mmHg) compared to valsartan 160 mg (8.7/8.8 mmHg). The difference in BP reductions between the 160/25 mg and 160/12.5 mg doses also reached statistical significance. In addition, a significantly greater percentage of patients responded (diastolic BP &lt;90 mmHg or reduction &ge;10 mmHg) with valsartan/hydrochlorothiazide 160/25 mg (68%) and 160/12.5 mg (62%) compared to valsartan 160 mg (49%).</p><p>In a double-blind, randomised, placebo-controlled, factorial design trial comparing various dose combinations of valsartan/hydrochlorothiazide to their respective components, significantly greater mean systolic/diastolic BP reductions were observed with the combination of valsartan/hydrochlorothiazide 160/12.5 mg (17.8/13.5 mmHg) and 160/25 mg (22.5/15.3 mmHg) compared to placebo (1.9/4.1 mmHg) and the respective monotherapies, i.e., hydrochlorothiazide 12.5 mg (7.3/7.2 mmHg), hydrochlorothiazide 25 mg (12.7/9.3 mmHg) and valsartan 160 mg (12.1/9.4 mmHg). In addition, a significantly greater percentage of patients responded (diastolic BP &lt;90 mmHg or reduction &ge;10 mmHg) with valsartan/hydrochlorothiazide 160/25 mg (81%) and valsartan/hydrochlorothiazide 160/12.5 mg (76%) compared to placebo (29%) and the respective monotherapies, i.e., hydrochlorothiazide 12.5 mg (41%), hydrochlorothiazide 25 mg (54%), and valsartan 160 mg (59%).</p><p><u>Valsartan/hydrochlorothiazide 80/12.5mg, 160/12.5 mg and 160/25mg Tablets:</u></p><p>Dose-dependent decreases in serum potassium occurred in controlled clinical studies with valsartan + hydrochlorothiazide. Reduction in serum potassium occurred more frequently in patients given 25 mg hydrochlorothiazide than in those given 12.5 mg hydrochlorothiazide. In controlled clinical trials with valsartan/hydrochlorothiazide the potassium lowering effect of hydrochlorothiazide was attenuated by the potassium-sparing effect of valsartan.</p><p>Beneficial effects of valsartan in combination with hydrochlorothiazide on cardiovascular mortality and morbidity are currently unknown.</p><p>Epidemiological studies have shown that long-term treatment with hydrochlorothiazide reduces the risk of cardiovascular mortality and morbidity.</p><p><em><u>Valsartan</u></em></p><p>Valsartan is an orally active and specific angiotensin II (Ang II) receptor antagonist. It acts selectively on the AT<sub>1</sub>&nbsp;receptor subtype, which is responsible for the known actions of angiotensin II. The increased plasma levels of Ang II following AT<sub>1</sub>&nbsp;receptor blockade with valsartan may stimulate the unblocked AT<sub>2</sub>&nbsp;receptor, which appears to counterbalance the effect of the AT<sub>1&nbsp;</sub>receptor. Valsartan does not exhibit any partial agonist activity at the AT<sub>1</sub>&nbsp;receptor and has much (about 20,000 fold) greater affinity for the AT<sub>1</sub>receptor than for the AT<sub>2</sub>&nbsp;receptor. Valsartan is not known to bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.</p><p>Valsartan does not inhibit ACE, also known as kininase II, which converts Ang I to Ang II and degrades bradykinin. Since there is no effect on ACE and no potentiation of bradykinin or substance P, angiotensin II antagonists are unlikely to be associated with coughing. In clinical trials where valsartan was compared with an ACE inhibitor, the incidence of dry cough was significantly (P &lt;0.05) lower in patients treated with valsartan than in those treated with an ACE inhibitor (2.6% versus 7.9% respectively). In a clinical trial of patients with a history of dry cough during ACE inhibitor therapy, 19.5% of trial subjects receiving valsartan and 19.0% of those receiving a thiazide diuretic experienced cough compared to 68.5% of those treated with an ACE inhibitor (P &lt;0.05).</p><p>Administration of valsartan to patients with hypertension results in reduction of blood pressure without affecting pulse rate. In most patients, after administration of a single oral dose, onset of antihypertensive activity occurs within 2 hours, and the peak reduction of blood pressure is achieved within 4-6 hours. The antihypertensive effect persists over 24 hours after dosing. During repeated dosing, the maximum reduction in blood pressure with any dose is generally attained within 2-4 weeks and is sustained during long-term therapy. Combined with hydrochlorothiazide, a significant additional reduction in blood pressure is achieved.</p><p>Abrupt withdrawal of valsartan has not been associated with rebound hypertension or other adverse clinical events.</p><p>In hypertensive patients with type 2 diabetes and microalbuminuria, valsartan has been shown to reduce the urinary excretion of albumin. The MARVAL (Micro Albuminuria Reduction with Valsartan) study assessed the reduction in urinary albumin excretion (UAE) with valsartan (80-160 mg/od) versus amlodipine (5-10 mg/od), in 332 type 2 diabetic patients (mean age: 58 years; 265 men) with microalbuminuria (valsartan: 58 &micro;g/min; amlodipine: 55.4 &micro;g/min), normal or high blood pressure and with preserved renal function (blood creatinine &lt;120 &micro;mol/l). At 24 weeks, UAE was reduced (p &lt;0.001) by 42% (&ndash;24.2 &micro;g/min; 95% CI: &ndash;40.4 to &ndash;19.1) with valsartan and approximately 3% (&ndash;1.7 &micro;g/min; 95% CI: &ndash;5.6 to 14.9) with amlodipine despite similar rates of blood pressure reduction in both groups. The Valsartan/hydrochlorothiazide Reduction of Proteinuria (DROP) study further examined the efficacy of valsartan in reducing UAE in 391 hypertensive patients (BP=150/88 mmHg) with type 2 diabetes, albuminuria (mean=102 &micro;g/min; 20&ndash;700 &micro;g/min) and preserved renal function (mean serum creatinine = 80 &micro;mol/l). Patients were randomised to one of 3 doses of valsartan (160, 320 and 640 mg/od) and treated for 30 weeks. The purpose of the study was to determine the optimal dose of valsartan for reducing UAE in hypertensive patients with type 2 diabetes. At 30 weeks, the percentage change in UAE was significantly reduced by 36% from baseline with valsartan 160 mg (95%CI: 22 to 47%), and by 44% with valsartan 320 mg (95%CI: 31 to 54%). It was concluded that 160-320 mg of valsartan produced clinically relevant reductions in UAE in hypertensive patients with type 2 diabetes.</p><p><u>Other: dual blockade of the renin-angiotensin-aldosterone system (RAAS)</u></p><p>Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.</p><p>ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</p><p>These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE inhibitors and angiotensin II receptor blockers.</p><p>ACE inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p><p><em><u>Hydrochlorothiazide</u></em></p><p>The site of action of thiazide diuretics is primarily in the renal distal convoluted tubule. It has been shown that there is a high-affinity receptor in the renal cortex as the primary binding site for the thiazide diuretic action and inhibition of NaCl transport in the distal convoluted tubule. The mode of action of thiazides is through inhibition of the Na<sup>+</sup>Cl<sup>-</sup>&nbsp;symporter perhaps by competing for the Cl<sup>-</sup>site, thereby affecting electrolyte reabsorption mechanisms: directly increasing sodium and chloride excretion to an approximately equal extent, and indirectly by this diuretic action reducing plasma volume, with consequent increases in plasma renin activity, aldosterone secretion and urinary potassium loss, and a decrease in serum potassium. The renin-aldosterone link is mediated by angiotensin II, so with co-administration of valsartan the reduction in serum potassium is less pronounced as observed under monotherapy with hydrochlorothiazide.</p><p><u>Non-melanoma skin cancer:</u></p><p>Based on available data from epidemiological studies, cumulative dose-dependent association between hydrochlorothiazide and NMSC has been observed. One study included a population comprised of 71,533 cases of BCC and of 8,629 cases of SCC matched to 1,430,833 and 172,462 population controls, respectively. High hydrochlorothiazide use (&ge;50,000 mg cumulative) was associated with an adjusted Odds Ratio (OR) of 1.29 (95% CI: 1.23-1.35) for BCC and 3.98 (95% CI: 3.68-4.31) for SCC. A clear cumulative dose response relationship was observed for both BCC and SCC. Another study showed a possible association between lip cancer (SCC) and exposure to hydrochlorothiazide: 633 cases of lip-cancer were matched with 63,067 population controls, using a risk-set sampling strategy. A cumulative dose- response relationship was demonstrated with an adjusted OR 2.1 (95% CI: 1.7-2.6) increasing to OR 3.9 (3.0-4.9) for high use (~25,000 mg) and OR 7.7 (5.7-10.5) for the highest cumulative dose (~100,000 mg) (see also section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Valsartan/hydrochlorothiazide</u></em></p><p>The systemic availability of hydrochlorothiazide is reduced by about 30% when co-administered with valsartan. The kinetics of valsartan are not markedly affected by the co-administration of hydrochlorothiazide. This observed interaction has no impact on the combined use of valsartan and hydrochlorothiazide, since controlled clinical trials have shown a clear anti-hypertensive effect, greater than that obtained with either active substance given alone, or placebo.</p><p><em><u>Valsartan</u></em></p><p><em>Absorption</em></p><p>Following oral administration of valsartan alone, peak plasma concentrations of valsartan are reached in 2&ndash;4 hours. Mean absolute bioavailability is 23%. Food decreases exposure (as measured by AUC) to valsartan by about 40% and peak plasma concentration (C<sub>max</sub>) by about 50%, although from about 8 h post dosing plasma valsartan concentrations are similar for the fed and fasted groups. This reduction in AUC is not, however, accompanied by a clinically significant reduction in the therapeutic effect, and valsartan can therefore be given either with or without food.</p><p><em>Distribution</em></p><p>The steady-state volume of distribution of valsartan after intravenous administration is about 17 litres, indicating that valsartan does not distribute into tissues extensively. Valsartan is highly bound to serum proteins (94 &ndash; 97%), mainly serum albumin.</p><p><em>Biotransformation</em></p><p>Valsartan is not biotransformed to a high extent as only about 20% of dose is recovered as metabolites. A hydroxy metabolite has been identified in plasma at low concentrations (less than 10% of the valsartan AUC). This metabolite is pharmacologically inactive.</p><p><em>Elimination</em></p><p>Valsartan shows multiexponential decay kinetics (t<sub>&frac12;&alpha;</sub>&nbsp;&lt;1 h and t<sub>&frac12;&szlig;</sub>&nbsp;about 9 h). Valsartan is primarily eliminated in faeces (about 83% of dose) and urine (about 13% of dose), mainly as unchanged drug. Following intravenous administration, plasma clearance of valsartan is about 2 l/h and its renal clearance is 0.62 l/h (about 30% of total clearance). The half-life of valsartan is 6 hours.</p><p><em><u>Hydrochlorothiazide</u></em></p><p><em>Absorption</em></p><p>The absorption of hydrochlorothiazide, after an oral dose, is rapid (t<sub>max</sub>&nbsp;about 2 h). The increase in mean AUC is linear and dose proportional in the therapeutic range.</p><p>The effect of food on hydrochlorothiazide absorption, if any, has little clinical significance. Absolute bioavailability of hydrochlorothiazide is 70% after oral administration.</p><p><em>Distribution</em></p><p>The apparent volume of distribution is 4&ndash;8 l/kg.</p><p>Circulating hydrochlorothiazide is bound to serum proteins (40&ndash;70%), mainly serum albumin. Hydrochlorothiazide also accumulates in erythrocytes at approximately 3 times the level in plasma.</p><p><em>Elimination</em></p><p>Hydrochlorothiazide is eliminated predominantly as unchanged drug. Hydrochlorothiazide is eliminated from plasma with a half-life averaging 6 to 15 hours in the terminal elimination phase. There is no change in the kinetics of hydrochlorothiazide on repeated dosing, and accumulation is minimal when dosed once daily. There is more than 95% of the absorbed dose being excreted as unchanged compound in the urine. The renal clearance is composed of passive filtration and active secretion into the renal tubule.</p><p><em><u>Special populations</u></em></p><p><em>Older people</em></p><p>A somewhat higher systemic exposure to valsartan was observed in some elderly subjects than in young subjects; however, this has not been shown to have any clinical significance.</p><p>Limited data suggest that the systemic clearance of hydrochlorothiazide is reduced in both healthy and hypertensive elderly subjects compared to young healthy volunteers.</p><p><em>Renal impairment</em></p><p>At the recommended dose of <strong>Avyska<sup>&reg;</sup> HCT<sup> </sup></strong>no dose adjustment is required for patients with a Glomerular Filtration Rate (GFR) of 30&ndash;70 ml/min.</p><p>In patients with severe renal impairment (GFR &lt;30 ml/min) and patients undergoing dialysis no data are available for valsartan/hydrochlorothiazide. Valsartan is highly bound to plasma protein and is not to be removed by dialysis, whereas clearance of hydrochlorothiazide will be achieved by dialysis.</p><p>In the presence of renal impairment, mean peak plasma levels and AUC values of hydrochlorothiazide are increased and the urinary excretion rate is reduced. In patients with mild to moderate renal impairment, a 3-fold increase in hydrochlorothiazide AUC has been observed. In patients with severe renal impairment an 8-fold increase in AUC has been observed. Hydrochlorothiazide is contraindicated in patients with severe renal impairment (see section 4.3).</p><p><em>Hepatic impairment</em></p><p>In a pharmacokinetics trial in patients with mild (n=6) to moderate (n=5) hepatic dysfunction, exposure to valsartan was increased approximately 2-fold compared with healthy volunteers (see sections 4.2 and 4.4).</p><p>There is no data available on the use of valsartan in patients with severe hepatic dysfunction (see section 4.3). Hepatic disease does not significantly affect the pharmacokinetics of hydrochlorothiazide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The potential toxicity of the valsartan - hydrochlorothiazide combination after oral administration was investigated in rats and marmosets in studies lasting up to six months. No findings emerged that would exclude the use of therapeutic doses in man.</p><p>The changes produced by the combination in the chronic toxicity studies are most likely to have been caused by the valsartan component. The toxicological target organ was the kidney, the reaction being more marked in the marmoset than the rat. The combination led to kidney damage (nephropathy with tubular basophilia, rises in plasma urea, plasma creatinine and serum potassium, increases in urine volume and urinary electrolytes from 30 mg/kg/day valsartan + 9 mg/kg/day hydrochlorothiazide in rats and 10 + 3 mg/kg/d in marmosets), probably by way of altered renal haemodynamics. These doses in rat, respectively, represent 0.9 and 3.5&ndash;times the maximum recommended human dose (MRHD) of valsartan and hydrochlorothiazide on a mg/m<sup>2</sup>basis. These doses in marmoset, respectively, represent 0.3 and 1.2&ndash;times the maximum recommended human dose (MRHD) of valsartan and hydrochlorothiazide on a mg/m<sup>2</sup>&nbsp;basis. (Calculations assume an oral dose of 320 mg/day valsartan in combination with 25 mg/day hydrochlorothiazide and a 60-kg patient).</p><p>High doses of the valsartan - hydrochlorothiazide combination caused falls in red blood cell indices (red cell count, haemoglobin, haematocrit, from 100 + 31 mg/kg/d in rats and 30 + 9 mg/kg/d in marmosets). These doses in rat, respectively, represent 3.0 and 12 times the maximum recommended human dose (MRHD) of valsartan and hydrochlorothiazide on a mg/m<sup>2</sup>&nbsp;basis. These doses in marmoset, respectively, represent 0.9 and 3.5 times the maximum recommended human dose (MRHD) of valsartan and hydrochlorothiazide on a mg/m<sup>2</sup>&nbsp;basis. (Calculations assume an oral dose of 320 mg/day valsartan in combination with 25 mg/day hydrochlorothiazide and a 60-kg patient).</p><p>In marmosets, damage was observed in the gastric mucosa (from 30 + 9 mg/kg/d). The combination also led in the kidney to hyperplasia of the afferent aterioles (at 600 + 188 mg/kg/d in rats and from 30 + 9 mg/kg/d in marmosets). These doses in marmoset, respectively, represent 0.9 and 3.5 times the maximum recommended human dose (MRHD) of valsartan and hydrochlorothiazide on a mg/m<sup>2</sup>&nbsp;basis. These doses in rat, respectively, represent 18 and 73 times the maximum recommended human dose (MRHD) of valsartan and hydrochlorothiazide on a mg/m<sup>2</sup>&nbsp;basis. (Calculations assume an oral dose of 320 mg/day valsartan in combination with 25 mg/day hydrochlorothiazide and a 60-kg patient).</p><p>The above mentioned effects appear to be due to the pharmacological effects of high valsartan doses (blockade of angiotensin II-induced inhibition of renin release, with stimulation of the renin-producing cells) and also occur with ACE inhibitors. These findings appear to have no relevance to the use of therapeutic doses of valsartan in humans.</p><p>The valsartan - hydrochlorothiazide combination was not tested for mutagenicity, chromosomal breakage or carcinogenicity, since there is no evidence of interaction between the two substances. However, these tests were performed separately with valsartan and hydrochlorothiazide, and produced no evidence of mutagenicity, chromosomal breakage or carcinogenicity.</p><p>In rats, maternally toxic doses of valsartan (600 mg/kg/day) during the last days of gestation and lactation led to lower survival, lower weight gain and delayed development (pinna detachment and ear-canal opening) in the offspring (see section 4.6). These doses in rats (600 mg/kg/day) are approximately 18 times the maximum recommended human dose on a mg/m<sup>2</sup>&nbsp;basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient). Similar findings were seen with valsartan/hydrochlorothiazide in rats and rabbits. In embryo-fetal development (Segment II) studies with valsartan/hydrochlorothiazide in rat and rabbit, there was no evidence of teratogenicity; however, fetotoxicity associated with maternal toxicity was observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The other ingredients are Microcrystalline cellulose, croscarmellose sodium, Povidone K30, Colloidal silicon dioxide, Magnesium stearate, Opadry OY-L White, FD&amp;C red # 40, FD&amp;C blue # 1, purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="3" cellpadding="0"><tbody><tr><td>&nbsp;</td><td><p>Not applicable.</p></td><td>&nbsp;</td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Avyska</strong><strong><sup>&reg;</sup></strong><strong><sup> </sup></strong><strong>HCT 80/12.5 mg:</strong> Light violet oblong normal biconvex film coated tablets, engraved with A1 on one face and plain on the other, presented in Alu/Alu blisters, intended for oral use.</p><p><strong>Pack size:</strong> 30 tablets (10 tablets / blister, 3 blister / pack)</p><p><strong>Avyska<sup>&reg; </sup>HCT 160/12.5 mg:</strong> Purple oblong deep biconvex film coated tablets, engraved with H21 on one face and and plain on the other face, presented in Alu/Alu blisters, intended for oral use.</p><p><strong>Pack size:</strong> 30 tablets (10 tablets / blister, 3 blister / pack)</p><p><strong>Avyska<sup>&reg; </sup>HCT 160/25 mg:</strong> Light violet oblong deep biconvex film coated tablets, engraved with H17 on one face and plain on the other face, presented in Alu/Alu blisters, intended for oral use.</p><p><strong>Pack size:</strong> 30 tablets (10 tablets / blister, 3 blister / pack)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Med City Pharma-KSA.
1st Industrial city, Phase 5, Jeddah –KSA.
Tel: 00966920003288
Mobile: 00966555786968
P.O .Box: 4072 - Jeddah 22429
E-mail: info@medcitypharma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                08/2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>